WO2010098488A1 - Composé arylimidazole et leur utilisation en tant qu'inhibiteurs de production de la protéine amyloïde bêta - Google Patents

Composé arylimidazole et leur utilisation en tant qu'inhibiteurs de production de la protéine amyloïde bêta Download PDF

Info

Publication number
WO2010098488A1
WO2010098488A1 PCT/JP2010/053370 JP2010053370W WO2010098488A1 WO 2010098488 A1 WO2010098488 A1 WO 2010098488A1 JP 2010053370 W JP2010053370 W JP 2010053370W WO 2010098488 A1 WO2010098488 A1 WO 2010098488A1
Authority
WO
WIPO (PCT)
Prior art keywords
group
compound
reaction
alkyl
methyl
Prior art date
Application number
PCT/JP2010/053370
Other languages
English (en)
Inventor
Teiji Kimura
Eriko Doi
Takashi Doko
Daisuke Shinmyo
Koichi Ito
Nobuaki Sato
Minako Hashizume
Toru Watanabe
Original Assignee
Eisai R&D Management Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Management Co., Ltd. filed Critical Eisai R&D Management Co., Ltd.
Publication of WO2010098488A1 publication Critical patent/WO2010098488A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Definitions

  • the present invention relates to a pharmaceutical, more particularly, to a polycyclic aryl imidazole derivative effective for the treatment of a neurodegenerative disease caused by amyloid- ⁇ (hereinafter referred to as A ⁇ ) such as Alzheimer's disease or Down's syndrome and a medicine, in particular, a medicine for the treatment of a disease caused by A ⁇ comprising the compound as an active ingredient.
  • a ⁇ amyloid- ⁇
  • Alzheimer's disease is a disease characterized by degeneration and loss of neurons as well as formation of senile plaques and neurofibrillary degeneration.
  • a symptom improving agent typified by an acetylcholinesterase inhibitor
  • a fundamental remedy to inhibit progression of the disease has not yet been developed. It is necessary to develop a method for controlling the cause of the onset of pathology in order to create a fundamental remedy for Alzheimer's disease.
  • a ⁇ -proteins as metabolites of amyloid precursor proteins are highly involved in degeneration and loss of neurons and onset of symptoms of dementia (see NON-PATENT DOCUMENTS 1 and 2, for example).
  • Main molecular species of A ⁇ -protein are A ⁇ 40 consisting of 40 amino acids and A ⁇ 42 with two amino acids added at the C-terminal.
  • the A ⁇ 40 and A ⁇ 42 are known to have high aggregability (see NON-PATENT DOCUMENT 3, for example) and to be main components of senile plaques (see NON-PATENT DOCUMENTS 3, 4 and 5, for example).
  • a ⁇ 40 and A ⁇ 42 are increased by mutation in APP and presenilin genes which is observed in familial Alzheimer's disease (see NON-PATENT DOCUMENTS 6, 7 and 8, for example). Accordingly, a compound that reduces the production of A ⁇ is expected as a progression inhibitor or prophylactic agent for Alzheimer's disease.
  • a ⁇ is produced by cleaving APP by ⁇ -secretase and subsequently by ⁇ -secretase. For this reason, attempts have been made to create ⁇ -secretase and ⁇ -secretase inhibitors in order to reduce A ⁇ production.
  • Many of these secretase inhibitors already known are, for example, peptides and peptide mimetics such as L-685,458 (see NON-PATENT DOCUMENT 9, for example), LY-411,575 (see NON-PATENT DOCUMENTS 10, 11 and 12, for example) and LY- 450, 139 (see NON-PATENT DOCUMENTS 13, 14 and 15).
  • Nonpeptidic compounds are, for example, MRK-560 (see NON-PATENT DOCUMENTS 16 and 17) and compounds having a plurality of aromatic rings as disclosed in PATENT DOCUMENTS 1 and 2.
  • the compound represented by the formula (VI) as disclosed in page 17 of the specification differs from the compound of the present invention in that the compound is limited to a compound having a 2-aminothiazolyl group as a main structure.
  • the compound represented by the formula (I) as disclosed in page 6 of the specification of Patent Document 2 differs from the compound of the present invention in that the compound is limited to a compound having an ethynylene, an ethenylene or methine linker described as X 1 .
  • PATENT DOCUMENT 1 WO 2004/110350
  • PATENT DOCUMENT 2 WO 2007/102580
  • NON-PATENT DOCUMENT 1 Klein WL, and seven others, Alzheimer's disease-affected brain: Presence of oligomeric A ⁇ ligands (ADDLs) suggests a molecular basis for reversible memory loss, Proceeding of the National Academy of Science USA, 2003, Sep, 2; 100 (18), p. 10417- 10422.
  • NON-PATENT DOCUMENT 2 Nitsch RM, and sixteen others, Antibodies against ⁇ -amyloid slow cognitive decline in Alzheimer's disease, Neuron, 2003, May 22; 38, p. 547-554.
  • NON-PATENT DOCUMENT 3 Jarrett JT, and two others, The carboxy terminus of the ⁇ amyloid protein is critical for the seeding of amyloid formation: Implications for the pathogenesis of Alzheimers 1 disease, Biochemistry, 1993, 32 (18), p. 4693-4697.
  • NON-PATENT DOCUMENT 4 Glenner GQ and one other, Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein, Biochemical and Biophysical Research Communications, 1984, May 16, 120 (3), p. 885-890.
  • NON-PATENT DOCUMENT 5 Masters CL, and five others, Amyloid plaque core protein in Alzheimer disease and Down syndrome, Proceeding of the National Academy of Science USA, 1985, Jun, 82 (12), p. 4245-4249.
  • NON-PATENT DOCUMENT 6 Gouras GK, and eleven others, Intraneuronal A ⁇ 42 accumulation in human brain, American Journal of Pathology, 2000, Jan, 156 (1), p. 15-20.
  • NON-PATENT DOCUMENT 7 Scheuner D, and twenty others, Secreted amyloid ⁇ -protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease, Nature Medicine, 1996, Aug, 2 (8), p. 864-870.
  • NON-PATENT DOCUMENT 8 Forman MS, and four others, Differential effects of the Swedish mutant amyloid precursor protein on ⁇ -amyloid accumulation and secretion in neurons and nonneuronal cells, The Journal of Biological Chemistry, 1997, Dec, 19, 272 (51), p. 32247- 32253.
  • NON-PATENT DOCUMENT 9 Shearman MS, and nine others, L-685, 458, an Aspartyl Protease Transition State Mimic, Is a Potent Inhibitor of Amyloid ⁇ -Protein Precursor ⁇ - Secretase Activity, Biochemistry, 2000, Aug, 1 , 39 (30), p. 8698-8704.
  • NON-PATENT DOCUMENT 10 Shearman MS, and six others, Catalytic Site-Directed ⁇ - Secretase Complex Inhibitors Do Not Discriminate Pharmacologically between Notch S3 and ⁇ - APP Clevages, Biochemistry, 2003, Jun, 24, 42 (24), p. 7580-7586.
  • NON-PATENT DOCUMENT 11 Lanz TA, and three others, Studies of A ⁇ pharmacodynamics in the brain, cerebrospinal fluid, and plasma in young (plaque-free) Tg2576 mice using the ⁇ - secretase inhibitor N2-[(2S)-2-(3,5-difluorophenyl)-2-hydroxyethanoyl]-N 1 -[(7S)-5-methyl-6- oxo-6,7-dihydro-5H-dibenzo[b,d]azepin-7-yl]-L-alaninamide (LY-411575), The Journal of Pharmacology and Experimental Therapeutics, 2004, Apr, 309 (1), p. 49-55.
  • NON-PATENT DOCUMENT 12 Wong GT, and twelve others, Chronic treatment with the ⁇ - secretase inhibitor LY-411, 575 inhibits ⁇ -amyloid peptide production and alters lymphopoiesis and intestinal cell differentiation, The Journal of Biological Chemistry, 2004, Mar, 26, 279 (13), p. 12876-12882.
  • NON-PATENT DOCUMENT 13 Gitter BD, and ten others, Stereoselective inhibition of amyloid beta peptide secretion by LY450139, a novel functional gamma secretase inhibitor, Neurology of Aging 2004, 25, sup2, p. 571.
  • NON-PATENT DOCUMENT 14 Lanz TA, and eighteen others, Concentration-dependent modulation of amyloid- ⁇ in vivo and in vitro using the ⁇ -secretase inhibitor, LY-450139, The Journal of Pharmacology and Experimantal Therapeutics, 2006, Nov, 319 (2) p. 924-933.
  • NON-PATENT DOCUMENT 15 Siemers ER, and thirteen others, Effects of a ⁇ -secretase inhibitor in a randamized study of patients with Alzheimer disease, Neurology, 2006, 66, p. 602- 604.
  • NON-PATENT DOCUMENT 16 Best JD, and nine others, In vivo characterization of A ⁇ (40) changes in brain and cerebrospinal fluid using the novel ⁇ -secretase inhibitor N-[cis-4-[(4- chlorophenyl)sulfonyl]-4-(2,5-difluorophenyl)cyclohexyl]- 1,1,1 -trifluoromethanesulphonlamide (MK-560) in the rat, The Journal of Pharmacology and Experimantal Therapeutics, 2006, May 317 (2) p. 786-790.
  • NON-PATENT DOCUMENT 17 Best JD, and thirteen others
  • the novel ⁇ -secretase inhibitor N- [cis-4-[(4-chlorophenyl)sulfonyl]-4-(2,5-difluorophenyl)cyclohexyl]- 1 ,1,1- trifluoromethanesulphonlamide (MK-560) reduces amylid plaque deposition without evidence notch-related pathology in the Tg2576 mouse, The Journal of Pharmacology and Experimantal Therapeutics, 2007, Feb, 320 (2) p. 552-558.
  • a compound that inhibits the production of A ⁇ from APP has been expected as a therapeutic or prophylactic agent for a disease caused by A ⁇ which is typified by Alzheimer's disease.
  • a nonpeptidic compound having high efficacy which inhibits the production of A ⁇ has not yet been known. Accordingly, there is a need for a novel low- molecular- weight compound that inhibits the production of A ⁇ .
  • the present invention relates to the following 1) to 12): 1 ) A compound represented by the formula [I] : [0008]
  • Ri and R 2 are the same or different and each represent a substituent selected from the following Substituent Group al ; m represents an integer of 0 to 3; n represents an integer of 0 to 2; W represents a nitrogen atom or a carbon atom;
  • Ring A represents a ring selected from the group consisting of the formulas [2] to [8]: [0010]
  • A* represents a bonding site to Xl ;
  • X 1 represents i) a single bond, ii) a Cl -6 alkylene group, iii) a vinylene group which may have 1 to 2 C2-6 alkyl groups or iv) -X 2 - (wherein X 2 represents -NR 3 -, -O-, -C(O)-, -NR 3 C(O)-, - C(O)NR 3 -, -S-, -S(O)- or -S(O) 2 - and R 3 represents a hydrogen atom, a Cl -6 alkyl group, a C3-6 cycloalkyl group, a C2-6 alkanoyl group or a Cl -6 alkylsulfonyl group); and Ring B represents a monocyclic or fused cyclic aromatic ring group selected from the group consisting of the formulas [10] to [27]: [0014]
  • each of which may have 1 to 3 substituents selected from the following Substituent Group cl
  • Substituent Group al a Cl-6 alkyl group, a C3-8 cycloalkyl group, a C2-6 alkenyl group, a Cl- 6 alkoxy group, a C2-6 alkenyloxy group, a C3-8 cycloalkyloxy group, an amino group (wherein the amino group may have one C2-6 alkanoyl group or Cl-6 alkylsulfonyl group or 1 to 2 Cl-6 alkyl groups or C3-8 cycloalkyl groups), a cyano group, a formyl group, a halogen atom, a hydroxyl group and a nitro group;
  • Substituent Group bl a Cl-6 alkyl group (wherein the alkyl group may be substituted with 1 to 3 halogen atoms), a C2-6 alkenyl group, a C3-8 cycloalkyl group, a C6-14 aryl group, a C6-14 aryl-Cl-6 alkyl group, a Cl-6 alkoxy group, a C2-6 alkenyloxy group, a C3-8 cycloalkyloxy group, a C2-6 alkanoyl group, a C4-9 cycloalkylcarbonyl group, a C7-15 aroyl group, a Cl-6 alkylsulfonyl group, a C2-6 alkenylsulfonyl group, a C3-8 cycloalkylsulfonyl group, a C6-14 arylsulfonyl group, a Cl-6 alkylthio group, a C2-6 alkenylthi
  • Substituent Group cl i) an amino group (wherein the amino group may have one C2-6 alkanoyl group, C 1-6 alkylsulfonyl group or C3-8 cycloalkylsulfonyl group or 1 to 2 C 1-6 alkyl groups or C3-8 cycloalkyl groups), ii) a cyano group, iii) a halogen atom, iv) a hydroxyl group and v) v-i) a C 1-6 alkyl group, v-ii) a C2-6 alkenyl group, v-iii) a C2-6 alkynyl group, v-iv) a Cl -6 alkoxy group, v- v) a Cl -6 alkylthio group, v-vi) a C 1-6 alkylaminocarbonyl group, v-vii) a Cl -6 alkylsulfonyl group, v-
  • Ring A is a ring selected from the group consisting of the formulas [3] to [8]: [0016]
  • Ring A is represented by the formula [3]: [0018]
  • Ring B is a phenyl group, a pyridyl group, an oxazolyl group, an imidazolyl group, an thiazolyl group, a dihydrobenzofuranyl group or a thienyl group;
  • Ri is a Cl -6 alkyl group or a halogen atom and m is 1 to 2;
  • the substituent for Ring A is selected from the group consisting of: a C 1-6 alkyl group (wherein the alkyl group may be substituted with 1 to 3 halogen atoms), a C3-8 cycloalkyl group, a C6-14 aryl group, a C6-14 aryl-Cl-6 alkyl group, a Cl-6 alkoxy group, a C3-8 cycloalkyloxy group, a C2-6 alkanoyl group, a C7-15 aroyl group, a Cl-6 alkylsulfonyl group, a C3-8 cycloalkylsulfonyl group, a C6-14 arylsulfonyl group, a cyano group, a formyl group, a halogen atom, a hydroxyl group and an oxo group;
  • a medicine comprising the compound or pharmacologically acceptable salt or ester thereof according to any one of 1) to 10) above as an active ingredient;
  • the compound of the general formula [I] or pharmacologically acceptable salt or ester thereof according to the present invention and the therapeutic agent for a disease caused by A ⁇ according to the present invention are novel inventions that have not yet been described in any documents.
  • the compound of the present invention can be converted to a chemical probe for capturing a target protein in a bioactive low-molecular compound.
  • the compound of the present invention can be converted to an affinity chromatography probe, a photoaffinity probe or the like by introducing a labeling group, a linker or the like into a moiety differing from a structural moiety essential for expression of activity of the compound by a technique described in J. Mass Spectrum. Soc. Jpn. Vol. 51, No. 5, 2003, p. 492-498 or WO 2007/139149, for example.
  • Examples of the labeling group, the linker or the like used for the chemical probe include groups shown in the following group consisting of (1) to (5):
  • protein labeling groups such as photoaffinity labeling groups (such as a benzoyl group, a benzophenone group, an azido group, a carbonylazido group, a diaziridine group, an enone group, a diazo group and a nitro group) and chemical affinity groups (such as a ketone group substituted at the ⁇ -carbon atom with a halogen atom, a carbamoyl group, an ester group, an alkylthio group, Michael acceptors such as ⁇ , ⁇ -unsaturated ketones and esters, and an oxirane group),
  • photoaffinity labeling groups such as a benzoyl group, a benzophenone group, an azido group, a carbonylazido group, a diaziridine group, an enone group, a diazo group and a nitro group
  • chemical affinity groups such as a ketone group substituted at the ⁇ -carbon atom with a halogen
  • cleavable linkers such as -S-S-, -0-Si-O-, monosaccharides (such as a glucose group and a galactose group) and disaccharides (such as lactose), and enzymatically cleavable oligopeptide linkers,
  • fishing tag groups such as biotin and 3-(4,4-difluoro-5,7-dimethyl-4H-3a,4a- diaza-4-bora-s-indacen-3-yl)propionyl,
  • detectable markers such as radioactive labeling groups such as 125 1, 32 P, 3 H and 14 C; fluorescence labeling groups such as fluorescein, rhodamine, dansyl, umbelliferone, 7- nitrofurazanyl and 3-(4,4-difluoro-5,7-dimethyl-4H-3a,4a-diaza-4-bora-s-indacen-3- yl)propionyl; chemiluminescent groups such as luciferin and luminol; and heavy metal ions such as lanthanoid metal ions and radium ions, and
  • groups bound to solid-phase carriers such as glass beads, glass beds, microtiter plates, agarose beads, agarose beds, polystyrene beads, polystyrene beds, nylon beads and nylon beds.
  • the probe When a probe is prepared by introducing a labeling group or the like selected from the group consisting of (1) to (5) above into the compound of the present invention in accordance with a method described in the above documents or the like, the probe can be used as a chemical probe for identification of labeled proteins useful for searching for novel drug targets, for example.
  • a structural formula of a compound may represent a certain isomer for convenience.
  • the present invention includes all isomers and isomer mixtures such as geometric isomers which can be generated from the structure of a compound, optical isomers based on asymmetric carbon, stereoisomers and tautomers.
  • the present invention is not limited to the description of a chemical formula for convenience and may include any one of the isomers or mixtures thereof.
  • the compound of the present invention may have an asymmetric carbon atom in the molecule and exist as an optically active compound or racemate, and the present invention includes each of the optically active compound and the racemate without limitations.
  • crystal polymorphs of the compound may be present, the compound is not limited thereto as well and may be present as a single crystal form or a mixture of single crystal forms.
  • the compound may be an anhydride or hydrate.
  • the present invention also includes isotopically-labelled compounds, which are identical to the compounds of formula (I), except that one or more atoms are replaced by an atom having an atomic mass or mass number different from the atomic mass or mass number uusually found in nature.
  • isotopes that can be incorporated into compounds of the invention include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorous, fluorine, iodine, and chlorine, such as 2 H, 3 H, 11 C, 14 C, 18 F, 35 S, 123 I and 125 I.
  • Isotopically-labelled compounds of the present invention for example those into which radioactive isotopes such as 3 H and/or 14 C are incorporated, are useful in drug and/or substrate tissue distribution assays. 3 H and 14 C are considered useful due to their ease of preparation and detectability. 11 C and 18 F isotopes are considered useful in PET (positron emission tomography), and 125 I isotopes are considered useful in SPECT (single photon emission computerized tomography), all useful in brain imaging.
  • Isotopically labelled compounds of formula (I) of this invention can generally be prepared by carrying out the procedures disclosed in the Schemes and/or in the Examples below, by substituting a readily available isotopically labelled reagent for a non-isotopically labelled reagent.
  • Alzheimer's disease includes a wide variety of conditions such as Alzheimer's disease (for example, refer to, Klein WL, and 7 others, Alzheimer's disease- affected brain: Presence of oligomeric A ⁇ ligands (ADDLs) suggests a molecular basis for reversible memory loss, Proceeding National Academy of Science USA, 2003, Sep 2, 100 (18), p. 10417-10422; Nitsch RM, and 16 others, Antibodies against ⁇ -amyloid slow cognitive decline in Alzheimer's disease, Neuron, 2003, May 22, 38 (4), p.
  • ADDLs oligomeric A ⁇ ligands
  • Amyloid plaque core protein in Alzheimer disease and Down syndrome Proceeding National Academy of Science USA, 1985, June, 82 (12), p. 4245-4249; Gouras GK, and 11 others, Intraneuronal A ⁇ 42 accumulation in human brain, American journal of pathology, 2000, Jan, 156 (1), p. 15-20; Scheuner D, and 20 others, Secreted amyloid ⁇ -protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease, Nature Medicine, 1996, Aug, 2 (8), p.
  • Pick disease for example, refer to, Yasuhara O, and 3 others, Accumulation of amyloid precursor protein in brain lesions of patients with Pick disease, Neuroscience Letters, 1994, Apr 25, 171 (1-2), p. 63-66
  • Down's syndrome for example, refer to, Teller JK, and 10 others, Presence of soluble amyloid ⁇ -peptide precedes amyloid plaque formation in Down's syndrome, Nature Medicine, 1996, Jan, 2 (1), p. 93-95; Tokuda T, and 6 others, Plasma levels of amyloid ⁇ proteins A ⁇ 1-40 and A ⁇ l-42 (43) are elevated in Down's syndrome, Annals of Neurology, 1997, Feb, 41 (2), p.
  • cerebrovascular angiopathy for example, refer to, Hayashi Y, and 9 others, Evidence for presenilin- 1 involvement in amyloid angiopathy in the Alzheimer's disease- affected brain, Brain Research, 1998, Apr 13, 789 (2), p. 307-314; Barelli H, and 15 others, Characterization of new polyclonal antibodies specific for 40 and 42 amino acid-long amyloid ⁇ peptides: their use to examine the cell biology of presenilins and the immunohistochemistry of sporadic Alzheimer's disease and cerebral amyloid angiopathy cases, Molecular Medicine, 1997, Oct, 3 (10), p.
  • hereditary cerebral hemorrhage with amyloidosis (Dutch type) (for example, refer to, Cras P, and 9 others, Presenile Alzheimer dementia characterized by amyloid angiopathy and large amyloid core type senile plaques in the APP 692AIa --> GIy mutation, Acta Neuropathologica (Berl), 1998, Sep, 96 (3), p. 253-260; Herzig MC, and 14 others, A ⁇ is targeted to the vasculature in a mouse model of hereditary cerebral hemorrhage with amyloidosis, Nature Neuroscience, 2004, Sep, 7 (9), p.
  • Dutch type hereditary cerebral hemorrhage with amyloidosis
  • Hereditary cerebral hemorrhage with amyloidosis in patients of Dutch origin is related to Alzheimer disease, Proceeding National Academy of Science USA, 1987, Aug, 84 (16), p. 5991-5994; Levy E, and 8 others, Mutation of the Alzheimer's disease amyloid gene in hereditary cerebral hemorrhage, Dutch type, Science, 1990, Jun 1, 248 (4959), p. 1124-1126), cognitive impairment (for example, refer to, Laws SM, and 7 others, Association between the presenilin-1 mutation Glu318Gly and complaints of memory impairment, Neurobiology of Aging, 2002, Jan-Feb, 23 (1), p.
  • memory disturbance/learning disturbance for example, refer to, Vaucher E, and 5 others, Object recognition memory and cholinergic parameters in mice expressing human presenilin 1 transgenes, Experimental Neurology, 2002 Jun, 175 (2), p. 398-406; Morgan D, and 14 others, A ⁇ peptide vaccination prevents memory loss in an animal model of Alzheimer's disease, Nature, 2000 Dec 21-28, 408 (6815), p. 982-985; Moran PM, and 3 others, Age-related learning deficits in transgenic mice expressing the 751 -amino acid isoform of human ⁇ -amyloid precursor protein, Proceeding
  • amyloidosis cerebral ischemia
  • Laws SM and 7 others, Association between the presenilin-1 mutation Glu318Gly and complaints of memory impairment, Neurobiology of Aging, 2002, Jan- Feb, 23 (1), p. 55-58; Koistinaho M, and 10 others, ⁇ -amyloid precursor protein transgenic mice that harbor diffuse A ⁇ deposits but do not form plaques show increased ischemic vulnerability: Role of inflammation, Proceeding National Academy of Science USA, 2002, Feb 5, 99 (3), p.
  • multiple sclerosis for example, refer to, Gehrmann J, and 4 others, Amyloid precursor protein (APP) expression in multiple sclerosis lesions, Glia, 1995, Oct, 15 (2), p. 141-51; Reynolds WF, and 6 others, Myeloperoxidase polymorphism is associated with gender specific risk for Alzheimer's disease, Experimental Neurology, 1999, Jan, 155 (1), p. 31-41), head injury, skull damage (for example, refer to, Smith DH, and 4 others, Protein accumulation in traumatic brain injury, NeuroMolecular Medicine, 2003, 4 (1-2), p.
  • APP Amyloid precursor protein
  • apraxia for example, refer to, Matsubara- Tsutsui M, and 7 others, Molecular evidence of presenilin 1 mutation in familial early onset dementia, American journal of Medical Genetics, 2002, Apr 8, 114 (3), p. 292-298
  • prion disease familial amyloid neuropathy, triplet repeat disease (for example, refer to, Kirkitadze MD, and 2 others, Paradigm shifts in Alzheimer's disease and other neurodegenerative disorders: the emerging role of oligomeric assemblies, Journal of Neuroscience Research, 2002, Sep 1, 69 (5), p.
  • Amyloid- ⁇ deposition in the cerebral cortex in Dementia with Lewy bodies is accompanied by a relative increase in A ⁇ PP mRNA isoforms containing the Kunitz protease inhibitor, Neurochemistry International, 2005, Feb, 46 (3), p. 253-260; Primavera J, and 4 others, Brain accumulation of amyloid- ⁇ in Non- Alzheimer Neurodegeneration, Journal of Alzheimer's Disease, 1999, Oct, 1 (3), p.
  • Parkinsonism-dementia complex for example, refer to, Schmidt ML, and 6 others, Amyloid plaques in Guam amyotrophic lateral sclerosis/ parkinsonism-dementia complex contain species of A ⁇ similar to those found in the amyloid plaques of Alzheimer's disease and pathological aging, Acta Neuropathologica (Berl), 1998, Feb, 95 (2), p. 117-122; Ito H, and 3 others, Demonstration of ⁇ amyloid protein- containing neurofibrillary tangles in parkinsonism-dementia complex on Guam, Neuropathology and applied neurobiology, 1991, Oct, 17 (5), p. 365-373), frontotemporal dementia and Parkinsonism linked to chromosome 17 (for example, refer to, Rosso SM, and 3 others,
  • Niemann-Pick disease for example, refer to, Jin LW, and 3 others, Intracellular accumulation of amyloidogenic fragments of amyloid- ⁇ precursor protein in neurons with Niemann-Pick type C defects is associated with endosomal abnormalities, American Journal of Pathology, 2004, Mar, 164 (3), p. 975-985
  • amyotrophic lateral sclerosis for example, refer to, Sasaki S, and another, Immunoreactivity of ⁇ -amyloid precursor protein in amyotrophic lateral sclerosis, Acta
  • Neuropathologica (Berl), 1999, May, 97 (5), p. 463-468; Tamaoka A, and 4 others, Increased amyloid ⁇ protein in the skin of patients with amyotrophic lateral sclerosis, Journal of neurology, 2000, Aug, 247 (8), p. 633-635; Hamilton RL, and another, Alzheimer disease pathology in amyotrophic lateral sclerosis, Acta Neuropathologica, 2004, Jun, 107 (6), p. 515-522; Turner BJ, and 6 others, Brain ⁇ -amyloidaccumulation in transgenic mice expressing mutant superoxide dismutase ⁇ Neurochemical Research, 2004, Dec, 29 (12), p.
  • hydrocephalus for example, refer to, Weller RO, Pathology of cerebrospinal fluid and interstitial fluid of the CNS: Significance for Alzheimer's disease, prion disorders and multiple sclerosis, Journal of Neuropathology and Experimental Neurology, 1998, Oct, 57 (10), p. 885-894; Silverberg GD, and 4 others, Alzheimer's disease, normal-pressure hydrocephalus, and senescent changes in CSF circulatory physiology: a hypothesis, Lancet neurology, 2003, Aug, 2 (8), p.
  • Cerebral amyloid angiopathy Accumulation of A ⁇ in interstitial fluid drainage pathways in Alzheimer's disease, Annals of the New York academy of sciences, 2000, Apr, 903, p. 110-117; Yow HY, and another, A role for cerebrovascular disease in determining the pattern of ⁇ -amyloid deposition in Alzheimer's disease, Neurology and applied neurobiology, 2002, 28, p. 149; Weller RO, and 4 others, Cerebrovascular disease is a major factor in the failure of elimination of A ⁇ from the aging human brain, Annals of the New York academy of sciences, 2002, Nov, 977, p.
  • paraparesis for example, refer to, O'Riordan S, and 7 others, Presenilin-1 mutation (E280G), spastic paraparesis, and cranial MRI white-matter abnormalities, Neurology, 2002, Oct 8, 59 (7), p. 1108-1110; Matsubara-Tsutsui M, and 7 others, Molecular evidence of presenilin 1 mutation in familial early onset dementia, American journal of Medical Genetics, 2002, Apr 8, 114 (3), p. 292-298; Smith MJ, and 11 others, Variable phenotype of Alzheimer's disease with spastic paraparesis, Annals of Neurology, 2001, 49 (1), p.
  • spasm for example, refer to, Singleton AB, and 13 others, Pathology of early-onset Alzheimer's disease cases bearing the Thrll3-114ins presenilin-1 mutation, Brain, 2000, Dec, 123 (PtI 2), p. 2467-2474
  • mild cognitive impairment for example, refer to, Gattaz WF, and 4 others, Platelet phospholipase A2 activity in Alzheimer's disease and mild cognitive impairment, Journal of Neural Transmission, 2004, May, 111 (5), p. 591-601 ; Assini A, and 14 others, Plasma levels of amyloid ⁇ -protein 42 are increased in women with mild cognitive impariment, Neurology, 2004, Sep 14, 63 (5), p.
  • arteriosclerosis for example, refer to, De Meyer GR, and 8 others, Platelet phagocytosis and processing of ⁇ -amyloid precursor protein as a mechanism of macrophage activation in atherosclerosis, Circulation Reserach, 2002, Jun 14, 90 (11), p. 1197-1204).
  • Substituent Group al refers to the following groups in the compound represented by the formula (I) effective for the treatment of a disease caused by A ⁇ according to the present invention.
  • the "Substituent Group al” refers to a C 1-6 alkyl group, a C3-8 cycloalkyl group, a C2-6 alkenyl group, a C 1-6 alkoxy group, a C2-6 alkenyloxy group, a C3-8 cycloalkyloxy group, an amino group (wherein the amino group may have one C2-6 alkanoyl group or C 1-6 alkylsulfonyl group or 1 to 2 C 1-6 alkyl groups or C3-8 cycloalkyl groups), a cyano group, a formyl group, a halogen atom, a hydroxyl group and a nitro group.
  • the "Substituent Group bl” refers to a C 1-6 alkyl group (wherein the alkyl group may be substituted with 1 to 3 halogen atoms), a C2-6 alkenyl group, a C3-8 cycloalkyl group, a C6-14 aryl group, a C6-14 aryl-Cl-6 alkyl group, a C 1-6 alkoxy group, a C2-6 alkenyloxy group, a C3-8 cycloalkyloxy group, a C2-6 alkanoyl group, a C4-9 cycloalkylcarbonyl group, a C7-15 aroyl group, a Cl -6 alkylsulfonyl group, a C2-6 alkenylsulfonyl group, a C3-8 cycloalkylsulfonyl group, a C6-14 arylsulfonyl group, a Cl -6 alkylthio group,
  • Substituent Group cl refers to an amino group (wherein the amino group may have one C2-6 alkanoyl group, C 1-6 alkylsulfonyl group or C3-8 cycloalkylsulfonyl group or 1 to 2 Cl -6 alkyl groups or C3-8 cycloalkyl groups), ii) a cyano group, iii) a halogen atom, iv) a hydroxyl group and v) v-i) a C 1-6 alkyl group, v-ii) a C2-6 alkenyl group, v-iii) a C2-6 alkynyl group, v-iv) a Cl -6 alkoxy group, v-v) a C 1-6 alkylthio group, v-vi) a C 1-6 alkylaminocarbonyl group, v-vii) a Cl -6 alkylsulfonyl group, v-vi
  • halogen atom refers to a fluorine atom, a chlorine atom, a bromine atom, an iodine atom or the like and is preferably a fluorine atom, a chlorine atom or a bromine atom.
  • C 1-6 alkyl group refers to an alkyl group having 1 to 6 carbon atoms.
  • the group include linear or branched alkyl groups such as a methyl group, an ethyl group, an n-propyl group, an isopropyl group, an n-butyl group, an isobutyl group, a tert-butyl group, an n-pentyl group, an isopentyl group, a neopentyl group, an n-hexyl group, a 1- methylpropyl group, an 1 ,2-dimethylpropyl group, a 1-ethylpropyl group, a l-methyl-2- ethylpropyl group, a l-ethyl-2-methylpropyl group, a 1,1,2-trimethylpropyl group, a 1- methylbutyl group, a 2-methylbutyl group, a 1,1-dimethylbutyl groups
  • C 1-6 alkylene group refers to an alkylene group having 1 to 6 carbon atoms.
  • the group include linear or branched alkylene groups such as a methylene group, an ethylene group, a methylmethylene group, a propylene group, a methylethylene group, an ethylmethylene group, a dimethylmethylene group, a butylene group, a methylpropylene group, an ethylethylene group, a dimethylethylene group, a propylmethylene group, a pentylene group and a hexylene group.
  • a methylene group, an ethylene group, a methylmethylene group, a propylene group, a methylethylene group, an ethylmethylene group and a dimethylmethylene group are preferable, for example.
  • C3-8 cycloalkyl group refers to a cyclic alkyl group having 3 to 8 carbon atoms.
  • Preferable examples of the group include a cyclopropyl group, a cyclobutyl group, a cyclopentyl group, a cyclohexyl group and a cycloheptyl group.
  • C2-6 alkenyl group refers to an alkenyl group having 2 to 6 carbon atoms.
  • Preferable examples of the group include linear or branched alkenyl groups such as a vinyl group, an allyl group, a 1-propenyl group, an isopropenyl group, a 1-buten-l-yl group, a 1-buten- 2-yl group, a 1 -buten-3-yl group, a 2-buten-l -yl group and a 2-buten-2-yl group.
  • C2-6 alkynyl group refers to an alkynyl group having 2 to 6 carbon atoms.
  • Preferable examples of the group include linear or branched alkynyl groups such as an ethynyl group, a 1-propynyl group, a 2-propynyl group, a butynyl group, a pentynyl group and a hexynyl group.
  • C3-8 cycloalkyloxy group refers to a cyclic alkyl group having 3 to 8 carbon atoms in which one hydrogen atom is replaced by an oxygen atom.
  • Preferable examples of the group include a cyclopropoxy group, a cyclobutoxy group, a cyclopentoxy group, a cyclohexoxy group, a cycloheptyloxy group and a cyclooctyloxy group.
  • C3-8 cycloalkylthio group refers to a cyclic alkyl group having 3 to 8 carbon atoms in which one hydrogen atom is replaced by a sulfur atom.
  • the group include a cyclopropylthio group, a cyclobutylthio group, a cyclopentylthio group, a cyclohexylthio group, a cycloheptylthio group and a cyclooctylthio group.
  • C 1-6 alkoxy group refers to an alkyl group having 1 to 6 carbon atoms in which a hydrogen atom is replaced by an oxygen atom.
  • the group include a methoxy group, an ethoxy group, an n-propoxy group, an isopropoxy group, an n- butoxy group, an isobutoxy group, a sec-butoxy group, a tert-butoxy group, an n-pentoxy group, an i-pentoxy group, a sec-pentoxy group, a tert-pentoxy group, an n-hexoxy group, an i-hexoxy group, a 1,2-dimethylpropoxy group, a 2-ethylpropoxy group, a l-methyl-2-ethylpropoxy group, a l-ethyl-2-methylpropoxy group, a 1,1,2-trimethylpropoxy group, a 1,1,2-trimethylpropoxy group, a 1,1-dimethylbutoxy group,
  • C 1-6 alkylthio group refers to an alkyl group having 1 to 6 carbon atoms in which one hydrogen atom is replaced by a sulfur atom.
  • the group include a methylthio group, an ethylthio group, an n-propylthio group, an isopropylthio group, an n-butylthio group, an isobutylthio group, a tert-butylthio group, an n-pentylthio group, an isopentylthio group, a neopentylthio group, an n-hexylthio group and a 1-methylpropylthio group.
  • C2-6 alkanoyl group refers to an alkyl group having 1 to 6 carbon atoms in which one hydrogen atom is substituted with a carbonyl group.
  • Preferable examples of the group include an acetyl group, a propionyl group and a butyryl group.
  • C 1-6 alkylsulfonyl group refers to an alkyl group having 1 to 6 carbon atoms in which one hydrogen atom is replaced by a sulfonyl group.
  • Preferable examples of the group include a methanesulfonyl group and an ethanesulfonyl group.
  • C2-6 alkenyloxy group refers to an alkenyl group having 2 to 6 carbon atoms in which one hydrogen atom is replaced by an oxygen atom.
  • the group include linear or branched alkenyloxy groups such as a vinyloxy group, an allyloxy group, a 1-propenyloxy group, an isopropenyloxy group, a 1-buten-l-yloxy group, a l-buten-2-yloxy group, a l-buten-3-yloxy group, a 2-buten-l-yloxy group and a 2-buten-2-yloxy group. [0043]
  • C2-6 alkenylthio group refers to an alkenyl group having 2 to 6 carbon atoms in which one hydrogen atom is replaced by a sulfur atom.
  • the group include linear or branched alkenylsulfonyl groups such as a vinylthio group, an allylthio group, a 2-propenylthio group, a 1-buten-l-ylthio group, a l-buten-2-ylthio group, a l-buten-3- ylthio group, a 2-buten-l-ylthio group and a 2-buten-2-ylthio group.
  • C2-6 alkenylsulfonyl group refers to an alkenyl group having 2 to 6 carbon atoms in which one hydrogen atom is replaced by a sulfonyl group.
  • the group include a vinylsulfonyl group, an allylsulfonyl group, a 2-propenylsulfonyl group, a 1- buten-1-ylsulfonyl group, a l-buten-2-ylsulfonyl group and a l-buten-3-ylsulfonyl group.
  • C3-8 cycloalkylsulfonyl group refers to a cyclic alkyl group having 3 to 8 carbon atoms in which one hydrogen atom is replaced by a sulfonyl group.
  • the group include a cyclopropylsulfonyl group, a cyclobutylsulfonyl group, a cyclopentylsulfonyl group, a cyclohexylsulfonyl group and a cycloheptylsulfonyl group.
  • C6-14 aryl group refers to a monocyclic, bicyclic or tricyclic aromatic hydrocarbon ring group having 6 to 14 carbon atoms.
  • Preferable examples of the group include 6- to 14-membered monocyclic, bicyclic or tricyclic aromatic hydrocarbon ring groups such as a phenyl group, an indenyl group, a naphthyl group, an azulenyl group, a heptalenyl group, a biphenyl group, a fluorenyl group, a phenalenyl group, an anthryl group and a phenanthryl group.
  • 6- to 14-membered monocyclic, bicyclic or tricyclic aromatic hydrocarbon ring groups such as a phenyl group, an indenyl group, a naphthyl group, an azulenyl group, a heptalenyl group, a biphenyl group, a fluorenyl group, a
  • the "C7-15 aroyl group” refers to the aforementioned C6-14 aryl group in which one hydrogen atom is replaced by a carbonyl group.
  • the group include a benzoyl group, an indenecarbonyl group, a naphthoyl group, a biphenylcarbonyl group, a fluorenylcarbonyl group, a phenanthrylcarbonyl group and an anthrylcarbonyl group.
  • C6-14 aryl-Cl-6 alkyl group refers to the aforementioned C 1-6 alkyl group in which one hydrogen atom is replaced by the aforementioned C6-14 aryl group.
  • Preferable examples of the group include a benzyl group, a phenethyl group, a phenylpropyl group, a naphthylmethyl group and a biphenylmethyl group.
  • C6-14 arylsulfonyl group refers to the aforementioned C6-14 aryl group in which one hydrogen atom is replaced by a sulfonyl group.
  • Preferable examples of the group include a benzenesulfonyl group, a naphthalenesulfonyl group and a biphenylsulfonyl group.
  • C4-9 cycloalkylcarbonyl group refers to a cyclic alkyl group having 3 to 8 carbon atoms substituted with a carbonyl group.
  • Preferable examples of the group include a cyclopropylcarbonyl group, a cyclobutylcarbonyl group, a cyclopentylcarbonyl group, a cyclohexylcarbonyl group and a cycloheptylcarbonyl group.
  • C 1-6 alkylaminocarbonyl group refers to an alkyl group having 1 to 6 carbon atoms in which one hydrogen atom is replaced by an aminocarbonyl group.
  • Preferable examples of the group include a methylaminocarbonyl group, an ethylaminocarbonyl group, a propylaminocarbonyl group, a butylaminocarbonyl group and a hexylaminocarbonyl group.
  • C 1-6 alkylaminosulfonyl group refers to an alkyl group having 1 to 6 carbon atoms in which one hydrogen atom is replaced by an aminosulfonyl group.
  • the group include a methylaminosulfonyl group, an ethylaminosulfonyl group, a propylaminosulfonyl group, a butylaminosulfonyl group and a hexylaminosulfonyl group.
  • the compound includes, for example, a tautomer represented by the formula: [0054]
  • Ring B may exist at any substitutable position on the ring.
  • Ring B may be connected to X 1 at any substitutable position on the ring.
  • Ring B is represented by the formula 19: [0057]
  • Ring B may be connected to Xi at a substitutable position indicated by any one of the following formulas 19-1 to 19-7: [0059]
  • the "pharmacologically acceptable salt” is not particularly limited insofar as it is a pharmacologically acceptable salt formed with the compound of the general formula [I] which is a therapeutic agent for a disease caused by A ⁇ . [0061]
  • the salt include hydrohalides (such as hydrofluorides, hydrochlorides, hydrobromides and hydroiodides), inorganic acid salts (such as sulfates, nitrates, perchlorates, phosphates, carbonates and bicarbonates), organic carboxylates (such as acetates, oxalates, maleates, tartrates, fumarates and citrates), organic sulfonates (such as methanesulfonates, trifluoromethanesulfonates, ethanesulfonates, benzenesulfonates, toluenesulfonates and camphorsulfonates), amino acid salts (such as aspartates and glutamates), quaternary amine salts, alkali metal salts (such as sodium salts and potassium salts) and alkali earth metal salts (such as magnesium salts and calcium salts).
  • hydrohalides such as hydrofluorides, hydrochlorides, hydrobromides
  • R 1 is a C 1-6 alkyl group or a halogen atom and n is an integer of 1 to 2; particularly preferably, R 1 is a C 1-6 alkyl group and n is an integer of 1 to 2; and most preferably, Rj is a methyl group and n is 1.
  • R 2 is a halogen atom, a hydroxyl group or a C 1-6 alkoxy group and n is an integer of 1 to 2; more preferably, R 2 is a C 1-6 alkoxy group and n is an integer of 1 to 2; and particularly preferably, R 2 is a methoxy group and n is 1.
  • X 1 is preferably i) a single bond, ii) a Cl -6 alkylene group which may have 1 to 2 Cl -6 alkyl groups or iii) -X 2 - (wherein X 2 represents -NR 3 - or -CO- and R 3 represents a hydrogen atom, a C 1-6 alkyl group, a C3-6 cycloalkyl group, a C2-6 alkanoyl group or a C 1-6 alkylsulfonyl group).
  • X 2 represents -NR 3 - or -CO-
  • R 3 represents a hydrogen atom, a C 1-6 alkyl group, a C3-6 cycloalkyl group, a C2-6 alkanoyl group or a C 1-6 alkylsulfonyl group.
  • Ring A is preferably represented by any one of the following formulas 3 to 8: [0066]
  • Ring B is preferably represented by any one of the formulas: [0071]
  • Substituent Group bl is preferably a substituent group consisting of (1) a C 1-6 alkyl group (wherein the alkyl group may be substituted with 1 to 3 halogen atoms), (2) a C3-8 cycloalkyl group, (3) a C6-14 aryl group, (4) a C6-14 aryl-Cl-6 alkyl group, (5) a C 1-6 alkoxy group, (6) a C3-8 cycloalkyloxy group, (7) a C2-6 alkanoyl group, (8) a C7-15 aroyl group, (9) a Cl-6 alkylsulfonyl group, (10) a C3-8 cycloalkylsulfonyl group, (11) a C6-14 arylsulfonyl group, (12) a cyano group, (13) a formyl group, (14) a halogen atom, (15) a hydroxyl group and (16) an ox
  • Substituent Group cl is preferably a substituent group consisting of (1) an amino group (wherein the amino group may have one C2-6 alkanoyl group, Cl-6 alkylsulfonyl group or C3-8 cycloalkylsulfonyl group or 1 to 2 Cl-6 alkyl groups or C3-8 cycloalkyl groups), (2) a cyano group, (3) a halogen atom, (4) a hydroxyl group and (5) (5)-l) a Cl-6 alkyl group, (5)-2) a Cl-6 alkoxy group, (5)-3) a Cl-6 alkylthio group and (5)-4) a phenyl group, each of which may have 1 to 3 substituents selected from the group consisting of a Cl-6 alkyl group and a halogen atom.
  • a pharmacologically acceptable salt thereof is particularly suitable, for example, and is useful as a therapeutic agent for a disease caused by amyloid- ⁇ such as Alzheimer's disease, senile dementia, Down's syndrome or amyloidosis.
  • amyloid- ⁇ such as Alzheimer's disease, senile dementia, Down's syndrome or amyloidosis.
  • the method comprises substituent conversion, substituent introduction and the like suitable for each step and known to a person skilled in the art. It is also obvious that, in order to prepare the compound of the present invention conveniently, all isomers and isomer mixtures such as geometric isomers which can be generated from the structure of the compound, optical isomers based on asymmetric carbon, stereoisomers, and tautomers can be prepared as a single compound by a technique known to a person skilled in the art which is suitable for each step such as fractional crystallization or column chromatography. [0081] General Preparation Method 1
  • Ri, R 2 , m, n, W, Ring A, X 1 and Ring B are as defined above;
  • X A represents a halogen atom such as a chlorine atom, a bromine atom or an iodine atom or a sulfonate group such as a methanesulfonate group, a p-toluenesulfonate group or a trifluoromethanesulfonate group;
  • X B represents a trialkylstannyl group, a boronic acid group or a boronate group such as a pinacol boronate group.
  • the above General Preparation Method 1 is a method for preparing the compound of the general formula [I] by subjecting to coupling reaction in Step 1-1 a compound of the general formula (a-1) and a compound of the general formula (b-2) or a method for preparing the compound of the general formula [I] by subjecting to coupling reaction in Step 1-1 a compound of the general formula (a-2) and a compound of the general formula (b-1) in which the substituents X A and X B are replaced by each other.
  • the coupling reaction in Step 1-1 varies according to the starting material and is not particularly limited insofar as the conditions are similar to those in this reaction.
  • a method known to a person skilled in the art may be used for the reaction.
  • Preferable examples of the method include Suzuki-Miyaura reaction (see A. Suzuki, “Chem. Rev.”, 1995, vol. 95, p. 2457, for example) and Stille coupling reaction (see J.K. Stille, "Angew. Chem. Int. Ed. Engl.”, 1986, vol. 25, p. 508, for example).
  • a halogen compound or trifluoromethanesulfonate compound of the general formula (a-1) is preferably coupled with 1.0 to 5.0 equivalents of a compound of the general formula (b-2) (wherein X B is preferably a boronic acid group, a boronate group such as a pinacol boronate group or the like) with respect to the compound of the general formula (a-1) in the presence of 0.01 to 0.5 equivalent of a transition metal catalyst with respect to the compound of the general formula (a-1 ), for example.
  • This reaction is preferably performed in the presence of a solvent from the viewpoint of handleability and stirring efficiency.
  • the solvent used varies according to the starting material and the transition metal catalyst used, and is not particularly limited insofar as it does not inhibit the reaction and allows the starting material to be dissolved therein to a certain extent.
  • the solvent include acetonitrile, tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane, benzene, toluene, xylene, l-methyl-2-pyrrolidone, N,N-dimethylformamide, water and a mixed solvent thereof.
  • the reaction temperature must be a temperature that can complete the coupling reaction, and is preferably room temperature to 200 0 C.
  • the transition metal catalyst is preferably a known palladium complex, and more preferably a known palladium complex such as palladium (II) acetate, dichlorobis(triphenylphosphine)palladium (II), tetrakis(triphenylphosphine)palladium (0) or tris(dibenzylideneacetone)dipalladium (0).
  • a phosphorus ligand (preferably triphenylphosphine, tri-o-tolylphosphine, tricyclohexylphosphine or tri-tert-butylphosphine, for example) may be appropriately added in order to make the reaction efficiently proceed.
  • a quaternary ammonium salt preferably tetrabutylammonium chloride or tetrabutylammonium bromide, for example, may also be appropriately added in order to make the reaction efficiently proceed.
  • a preferable result may be achieved in the presence of a base.
  • the base used at this time varies according to the starting material, the solvent used and the like, and is not particularly limited.
  • the base include sodium hydroxide, barium hydroxide, potassium fluoride, cesium fluoride, sodium carbonate, potassium carbonate, cesium carbonate and potassium phosphate.
  • the reaction is completed in 1 to 24 hours, and the progress of the reaction can be monitored by a known chromatography technique.
  • a halogen compound or trifluoromethanesulfonate compound of the general formula (a-1) is preferably coupled with 1.0 to 5.0 equivalents of a compound of the general formula (b-2) (wherein X B is preferably a trialkylstannyl group) with respect to the compound of the general formula (a-1) in the presence of 0.01 to 0.2 equivalent of a transition metal catalyst with respect to the compound of the general formula (a-1), for example. It is preferable to appropriately use in this reaction 0.1 to 5.0 equivalents of copper (I) halide or/and lithium chloride in order to make the reaction efficiently proceed.
  • the solvent used in this reaction include toluene, xylene, N,N-dimethylformamide, N,N-dimethylacetamide, l-methyl-2-pyrrolidone and dimethyl sulfoxide.
  • the reaction temperature must be a temperature that can complete the coupling reaction, and is preferably room temperature to 150 0 C.
  • the preferable transition metal catalyst is a palladium complex, preferably a known palladium complex such as palladium (II) acetate, dichlorobis(triphenylphosphine)palladium (II), tetrakis(triphenylphosphine)palladium (0) or tris(dibenzylideneacetone)dipalladium (0), for example, and more preferably palladium (II) acetate, tetrakis(triphenylphosphine)palladium (0) or tris(dibenzylideneacetone)dipalladium (0), for example.
  • a known palladium complex such as palladium (II) acetate, dichlorobis(triphenylphosphine)palladium (II), tetrakis(triphenylphosphine)palladium (0) or tris(dibenzylideneacetone)dipalladium (0), for example, and more preferably
  • a phosphorus ligand (preferably triphenylphosphine, tri-o-tolylphosphine, 1,3- bis(diphenylphosphino)propane or tri-tert-butylphosphine, for example) may be appropriately added, for example, in order to make the reaction efficiently proceed.
  • This reaction is performed preferably in an inert gas atmosphere, and more preferably in a nitrogen or argon atmosphere. Under preferable reaction conditions, the reaction is completed in 1 to 24 hours, and the progress of the reaction can be monitored by a known chromatography technique.
  • Step 1-2 is an example of a method for preparing a compound of the general formula (a-2) and a compound of the general formula (b-2) in which the substituents X A and XB are replaced by each other.
  • This step varies according to the starting material and is not particularly limited insofar as the conditions are similar to those in this reaction.
  • a method known to a person skilled in the art may be used for the reaction. It is possible to use methods similar to preparation methods such as Suzuki-Miyaura reaction (see A. Suzuki, “Chem. Rev.”, 1995, vol. 95, p. 2457, for example) and Stille coupling reaction (see J.K. Stille, "Angew. Chem. Int. Ed. Engl.”, 1986, vol. 25, p. 508, for example).
  • Preparation of compound of general formula (a-1) The following formula shows an example of preparation of the compound of the general formula (a-1). [0090]
  • R 1 , R 2 , m, n, W and X A are as defined above; R A and R B are as defined for R 1 above; Li represents a halogen atom such as a chlorine atom, a bromine atom or an iodine atom or a sulfonate group such as a methanesulfonate group, a p-toluenesulfonate group or a trifluoromethanesulfonate group; and L 2 represents a halogen atom such as a fluorine atom, a chlorine atom, a bromine atom or an iodine atom, a sulfonate group such as a methanesulfonate group, a p-toluenesulfonate group or a trifluoromethanesulfonate group or a boronic acid group.
  • halogen atom such as a chlorine atom, a bromine atom or an
  • the compound of the general formula (a-1) can be prepared from an amine compound (a-3) as a starting material through formylation in Step 2-1, alkylation reaction in Step 2-2 and formation of an imidazole ring in Step 2-3, or can be prepared from a compound of the general formula (a-4) as a starting material by coupling reaction in Step 2-4.
  • Step 2-1 varies according to the starting material and is not particularly limited insofar as the conditions are similar to those in this reaction.
  • a method known to a person skilled in the art may be used for the reaction.
  • a method reported in many documents or the like T. Greene et al., "Protective Groups in Organic Synthesis", John Wiley & Sons, Inc., New York, 1981, for example) may be used.
  • Step 2-2 varies according to the starting material and is not particularly limited insofar as the conditions are similar to those in this reaction.
  • a method known to a person skilled in the art may be used for the reaction.
  • Preferable examples of the method include a method of stirring a compound of the general formula (a-5) and 1.0 to 10.0 equivalents of a compound of the general formula (c-1) with respect to the compound of the general formula (a- 5) in a solvent in the presence of 1.0 to 10.0 equivalents of a base with respect to the compound of the general formula (a-5).
  • the base used varies according to the starting material and is not particularly limited.
  • the base include alkali metal hydrides (such as sodium hydride and lithium hydride), alkali metal salts (such as potassium carbonate, sodium carbonate and cesium carbonate) and metal alkoxides (such as sodium methoxide and potassium tert-butoxide).
  • alkali metal hydrides such as sodium hydride and lithium hydride
  • alkali metal salts such as potassium carbonate, sodium carbonate and cesium carbonate
  • metal alkoxides such as sodium methoxide and potassium tert-butoxide.
  • the solvent used varies according to the starting material, and is not particularly limited insofar as it does not inhibit the reaction and allows the starting material to be dissolved therein to a certain extent.
  • the solvent include ether solvents such as tetrahydrofuran, 1,4-dioxane and diethyl ether; halogenated solvents such as methylene chloride, 1,2-dichloroethane and chloroform; polar solvents such as N,N-dimethylformamide and N- methylpyrrolidone; non-polar solvents such as toluene and benzene; and mixtures thereof.
  • the reaction temperature must be a temperature that can complete the reaction without promoting formation of an undesirable by-product, and is preferably 0 0 C to 200 0 C, for example.
  • Step 2-3 varies according to the starting material and is not particularly limited insofar as the conditions are similar to those in this reaction.
  • a method known to a person skilled in the art may be used for the reaction.
  • a method reported in many documents or the like such as described in The Chemistry of Heterocyclic Compounds. Imidazole and Derivatives, Part I, p. 33, Inters. Publish. 1953) may be used.
  • Preferable examples of the method include a method for preparing the compound of the general formula (a-1) by forming an imidazole ring from a compound of the general formula (a-6) and ammonia, ammonium salt, formamide or the like as a nitrogen source.
  • the solvent used is not particularly limited insofar as it does not inhibit the reaction and allows the starting material to be dissolved therein to a certain extent.
  • the solvent include non-polar solvents such as toluene and benzene; alcohol solvents such as methanol and ethanol; organic acids such as acetic acid or trifluoroacetic acid, sulfonic acids such as p-toluenesulfonic acid and trifluoromethanesulfonic acid; water; and mixtures thereof.
  • Formamide may optionally be used as a nitrogen atom source and as a solvent.
  • the reaction temperature must be a temperature that can complete the reaction without promoting formation of an undesirable by-product, and is preferably room temperature to 250 0 C, for example. The yield may be improved when the reaction is performed using a tight container.
  • the reaction is completed in 1 to 24 hours, and the progress of the reaction can be monitored by a known chromatography technique.
  • An undesirable by-product can be removed by a technique known to a person skilled in the art such as a conventional chromatography technique, extraction or/and crystallization.
  • the coupling reaction in Step 2-4 varies according to the starting material and is not particularly limited insofar as the conditions are similar to those in this reaction.
  • a method known to a person skilled in the art may be used for the reaction.
  • a method reported in many documents or the like (such as described in D.D. Davey et al., "J. Med. Chem.”, 1991, vol. 34, p. 2671 -2677) may be used.
  • Examples of the method include a method of stirring a compound of the general formula (a-4) (wherein L 2 is preferably a halogen atom or the like) and 1.0 to 5.0 equivalents of an imidazole compound (c-2) with respect to the compound of the general formula (a-4) in a solvent in the presence or absence of 1.0 to 5.0 equivalents of a base with respect to the compound of the general formula (a-4).
  • the base used include sodium hydride, sodium hydroxide, potassium hydroxide, potassium carbonate, sodium carbonate, cesium carbonate, barium carbonate, pyridine, lutidine and triethylamine.
  • the solvent used varies according to the starting material, and is not particularly limited insofar as it does not inhibit the reaction and allows the starting material to be dissolved therein to a certain extent.
  • the solvent include acetonitrile, tetrahydrofuran, dimethyl sulfoxide, N,N-dimethylformamide and N-methylpyrrolidone.
  • the base may optionally be used as a solvent.
  • the reaction temperature must be a temperature that can complete the reaction without promoting formation of an undesirable by-product, and is preferably room temperature to 150 0 C, for example. Under preferable reaction conditions, the reaction is completed in 1 to 24 hours, and the progress of the reaction can be monitored by a known chromatography technique. An undesirable by-product can be removed by a technique known to a person skilled in the art such as a conventional chromatography technique or/and crystallization. [0097]
  • Examples of the coupling reaction in Step 2-4 include a method of stirring a compound of the general formula (a-4) (wherein L 2 is preferably a boronic acid group or the like) in a solvent in the presence of a copper catalyst (such as described in J.P. Collman et al., "Org. Letters.”, 2000, vol. 2, p. 1233-1236).
  • Preferable examples of the method include a method of stirring a compound of the general formula (a-4) and 0.1 to 10.0 equivalents of an imidazole compound (c-2) with respect to the compound of the general formula (a-4) in a solvent in the presence of 0.01 to 1.0 equivalent of a copper reagent such as copper, copper bromide or copper iodide with respect to the compound of the general formula (a-4).
  • a copper reagent such as copper, copper bromide or copper iodide with respect to the compound of the general formula (a-4).
  • the copper reagent used varies according to the starting material and is not particularly limited.
  • the copper reagent include copper (I) halide, copper (II) acetate, copper (II) nitrate and di- ⁇ -hydroxo-bis[(N,N,N',N'-tetramethylethylenediamine)copper (II)] chloride.
  • the solvent used varies according to the starting material, the reagent and the like, and is not particularly limited insofar as it does not inhibit the reaction and allows the starting material to be dissolved therein to a certain extent.
  • the solvent include ether solvents such as tetrahydrofuran, 1,4-dioxane and diethyl ether; halogenated solvents such as methylene chloride, 1,2-dichloroethane and chloroform; polar solvents such as ethyl acetate, N,N-dimethylformamide and N-methylpyrrolidone; non-polar solvents such as toluene, benzene and dichlorobenzene; and mixtures thereof.
  • a base may be used depending on the starting material, the reagent and the like.
  • the base include organic bases such as triethylamine, pyridine and tetramethylethylenediamine; alkali metal salts such as potassium carbonate, sodium carbonate, potassium acetate, sodium acetate and cesium carbonate; and metal alkoxides such as sodium methoxide and potassium tert-butoxide.
  • the reaction temperature must be a temperature that can complete the reaction without promoting formation of an undesirable by-product, and is preferably room temperature to 200 0 C, for example. Good results such as reduction in the reaction time and improvement of the yield can be achieved when the reaction is performed in an oxygen atmosphere or air stream. Under preferable reaction conditions, the reaction is completed in 1 to 24 hours, and the progress of the reaction can be monitored by a known chromatography technique. An undesirable by-product can be removed by a technique known to a person skilled in the art such as a conventional chromatography technique, extraction or/and crystallization.
  • L 3 represents a halogen atom such as a fluorine atom, a chlorine atom, a bromine atom or an iodine atom, a sulfonate group such as a methanesulfonate group, a p-toluenesulfonate group or a trifluoromethanesulfonate group, a boronic acid group, a nitro group or an azido group.
  • halogen atom such as a fluorine atom, a chlorine atom, a bromine atom or an iodine atom
  • a sulfonate group such as a methanesulfonate group, a p-toluenesulfonate group or a trifluoromethanesulfonate group
  • a boronic acid group such as a nitro group or an azido group.
  • the compound of the general formula (b-1) can be prepared from a compound of the general formula (d-1) as a starting material through condensation reaction in Step 3-1, reduction reaction in Step 3-2 and Sandmeyer reaction in Step 3-3.
  • the coupling reaction in Step 3-1 varies according to the starting material and is not particularly limited insofar as the conditions are similar to those in this reaction. A method known to a person skilled in the art may be used for the reaction.
  • Examples of the method include a method of stirring a compound of the general formula (d-1) and 1.0 to 5.0 equivalents of a compound of the general formula (d-2) with respect to the compound of the general formula (d-1) in a solvent in the presence or absence of 1.0 to 5.0 equivalents of a base with respect to the compound of the general formula (d-1).
  • Preferable examples of the base used include sodium hydride, sodium hydroxide, potassium hydroxide, potassium carbonate, sodium carbonate, cesium carbonate, barium carbonate, pyridine, lutidine and triethylamine.
  • the solvent used varies according to the starting material, and is not particularly limited insofar as it does not inhibit the reaction and allows the starting material to be dissolved therein to a certain extent.
  • the solvent include acetonitrile, tetrahydrofuran, dimethyl sulfoxide, N,N-dimethylformamide and N-methylpyrrolidone.
  • the base may optionally be used as a solvent.
  • the reaction temperature must be a temperature that can complete the reaction without promoting formation of an undesirable by-product, and is preferably room temperature to 150 0 C, for example. Under preferable reaction conditions, the reaction is completed in 1 to 24 hours, and the progress of the reaction can be monitored by a known chromatography technique. An undesirable by-product can be removed by a technique known to a person skilled in the art such as a conventional chromatography technique or/and crystallization. [0103]
  • the nitro group reduction reaction in Step 3-2 varies according to the starting material and is not particularly limited insofar as the conditions are similar to those in this reaction.
  • a reduction reaction known to a person skilled in the art may be used for the reaction.
  • a method reported in many documents or the like such as described in The Chemical Society of Japan (ed.), Jikken Kagaku Koza (Courses in Experimental Chemistry), 4th edition (vol. 20) Yuki Gosei (Organic Synthesis) [IV], Maruzen Co., Ltd., November 1992, p. 279-280) may be used. [0104]
  • the Sandmeyer reaction in Step 3-3 varies according to the starting material and is not particularly limited insofar as the conditions are similar to those in this reaction.
  • a method known to a person skilled in the art may be used for the reaction.
  • a method reported in many documents or the like such as described in The Chemical Society of Japan (ed.), Jikken Kagaku Koza (Courses in Experimental Chemistry), 4th edition (vol. 19) Yuki Gosei (Organic Synthesis) [I], Maruzen Co., Ltd., November 1992, p. 450-453) may be used.
  • the compound of the formula (d-1) and the compound of the formula (d-2) are known or commercially available compounds or are compounds that can be prepared from these compounds by a conventional method.
  • R 1 , R 2 , X 1 , m, n, W, Ring A and Ring B are as defined above;
  • Pi represents an imidate-protecting group such as a methyl group, an ethyl group, a benzyl group or an allyl group.
  • the above General Preparation Method 2 shows an example of a method for preparing the compound of the general formula [I] by subjecting a compound of the general formula (a-7) and a compound of the general formula (e-1) to cyclization reaction in Step 4-1. [0109]
  • the Ring A formation reaction in Step 4-1 varies according to the starting material and is not particularly limited insofar as the conditions are similar to those in this reaction.
  • a method known to a person skilled in the art may be used for the reaction.
  • Preferable examples of the method include a method of stirring a compound of the general formula (a-7) and 1.0 to 5.0 equivalents of a compound of the general formula (e-1) with respect to the compound of the general formula (a-7) in a solvent in the presence of 1.0 to 10.0 equivalents of a base with respect to the compound of the general formula (a-7).
  • This reaction is preferably performed in the presence of a solvent from the viewpoint of handleability and stirring efficiency.
  • the solvent used varies according to the starting material, and is not particularly limited insofar as it does not inhibit the reaction and allows the starting material to be dissolved therein to a certain extent.
  • the solvent include alcohol solvents such as methanol, ethanol and tert-butanol; ether solvents such as tetrahydrofuran, 1,4- dioxane and diethyl ether; halogenated solvents such as methylene chloride, 1,2-dichloroethane and chloroform; polar solvents such as acetonitrile, propionitrile, N,N-dimethylformamide and N-methylpyrrolidone; non-polar solvents such as toluene and benzene; and mixtures thereof.
  • the base used varies according to the starting material and is not particularly limited.
  • the base include alkali metal hydrides (such as sodium hydride and lithium hydride), alkali metal salts (such as potassium carbonate, sodium carbonate and cesium carbonate), metal alkoxides (such as sodium methoxide and potassium tert-butoxide) and organic bases (such as triethylamine, N,N-diisopropylethylamine, l,8-diazabicyclo[5.4.0]undec-7-ene and imidazole).
  • the reaction temperature must be a temperature that can complete the reaction without promoting formation of an undesirable by-product, and is preferably room temperature to 200 0 C, for example.
  • the reaction is completed in 1 to 7 days, and the progress of the reaction can be monitored by a known chromatography technique.
  • An undesirable by-product can be removed by a technique known to a person skilled in the art such as a conventional chromatography technique, extraction or/and crystallization.
  • R 1 , R 2 , m, n, X A and W are as defined above;
  • P 2 represents a nitrogen-protecting group such as a tert-butoxycarbonyl group or a benzyloxycarbonyl group; and
  • M A represents a metal such as zinc or copper.
  • the compound of the general formula (a-7) can be prepared from a compound of the general formula (a-1) as a starting material through coupling reaction in Step 5-1, hydrolysis reaction in Step 5-2, hydrazidation in Step 5-3 and deprotection reaction in Step 5-4. [0114]
  • the coupling reaction in Step 5-1 varies according to the starting material and is not particularly limited insofar as the conditions are similar to those in this reaction.
  • a method known to a person skilled in the art may be used for the reaction.
  • a halogen compound or trifluoromethanesulfonate compound of the general formula (a-1) is preferably coupled with 1.0 to 5.0 equivalents of a metal cyanide such as zinc (II) cyanide represented by the general formula (h-1) with respect to the compound of the general formula (a-1) in the presence of 0.01 to 0.2 equivalent of a transition metal catalyst with respect to the compound of the general formula (a- 1), for example.
  • This reaction is preferably performed in the presence of a solvent from the viewpoint of handleability and stirring efficiency.
  • the solvent used varies according to the starting material and the transition metal catalyst used, and is not particularly limited insofar as it does not inhibit the reaction and allows the starting material to be dissolved therein to a certain extent.
  • the solvent include acetonitrile, tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane, benzene, toluene, xylene, l-methyl-2-pyrrolidone and N 5 N- dimethylformamide.
  • the reaction temperature must be a temperature that can complete the coupling reaction, and is preferably room temperature to 150 0 C. This reaction is performed preferably in an inert gas atmosphere, and more preferably in a nitrogen or argon atmosphere.
  • the transition metal catalyst is preferably a palladium complex, for example, and more preferably a known palladium complex such as palladium (II) acetate, dichlorobis(triphenylphosphine)palladium (II), tetrakis(triphenylphosphine)palladium (0) or tris(dibenzylideneacetone)dipalladium (0). It is also preferable to appropriately add a phosphine ligand (preferably triphenylphosphine, tri-o-tolylphosphine, tri-tert-butylphosphine or 2-(di-tert-butylphosphino)biphenyl, for example) in order to make the reaction efficiently proceed.
  • a phosphine ligand preferably triphenylphosphine, tri-o-tolylphosphine, tri-tert-butylphosphine or 2-(di-tert-butylphosphin
  • a preferable result may be achieved in the presence of a base.
  • the base used is not particularly limited insofar as it is used in a coupling reaction similar to this reaction.
  • Preferable examples of the base include triethylamine, N,N-diisopropylethylamine, N,N- dicyclohexylmethylamine and tetrabutylammonium chloride.
  • the reaction is completed in 1 to 24 hours, and the progress of the reaction can be monitored by a known chromatography technique.
  • the nitrile hydrolysis reaction in Step 5-2 varies according to the starting material and is not particularly limited insofar as the conditions are similar to those in this reaction.
  • a method known to a person skilled in the art may be used for the reaction.
  • the hydrazidation reaction in Step 5-3 varies according to the starting material and is not particularly limited insofar as the conditions are similar to those in this reaction.
  • An amidation reaction known to a person skilled in the art may be used for the reaction.
  • a method reported in many documents or the like (such as described in The Chemical Society of Japan
  • the deprotection reaction in Step 5-4 varies according to the starting material and is not particularly limited insofar as the conditions are similar to those in this reaction.
  • a deprotection reaction known to a person skilled in the art may be used for the reaction.
  • a method reported in many documents or the like see T. Greene et al., "Protective Groups in
  • the compound of the formula (f-1) and the compound of the formula (h-1) are known or commercially available compounds or are compounds that can be prepared from these compounds by a conventional method. [0118]
  • the compound of the general formula (e-1) can be prepared from a compound of the general formula (e-2) as a starting material through imidation in Step 6-1.
  • Step 6-1 varies according to the starting material and is not particularly limited insofar as the conditions are similar to those in this reaction.
  • a method known to a person skilled in the art may be used for the reaction.
  • Preferable examples of the method include a method of stirring the compound of the general formula (e-2) in an alcohol solvent in the presence of 5.0 to 100.0 equivalents of an acid with respect to the compound of the general formula (e-2).
  • the acid used varies according to the starting material and is not particularly limited.
  • Preferable examples of the acid include hydrogen chloride gas and acetyl chloride.
  • the solvent used varies according to the starting material, and is not particularly limited insofar as it does not inhibit the reaction and allows the starting material to be dissolved therein to a certain extent.
  • the solvent include alcoholic solvents such as methanol, ethanol and tert-butanol.
  • the solvent also include the mixed solvents of halogenated solvents such as a methylene chloride, 1,2-dichloroethane and chloroform; polar solvents such as N,N-dimethylformamide and N-methylpyrrolidone; non-polar solvents such as toluene and benzene; and mixture thereof with alcoholic solvents.
  • the reaction temperature must be a temperature that can complete the reaction without promoting formation of an undesirable by-product, and is preferably 0 0 C to 100 0 C, for example. Under preferable reaction conditions, the reaction is completed in 1 to 7 days, and the progress of the reaction can be monitored by a known chromatography technique. An undesirable by-product can be removed by a technique known to a person skilled in the art such as a conventional chromatography technique, extraction or/and crystallization.
  • the compound of the formula (e-2) is a known or commercially available compound or is a compound that can be prepared from such a compound by a conventional method. [0122] General Preparation Method 3
  • R 1 , R 2 , m, n, W, X 1 and Ring B are as defined above.
  • the above General Preparation Method 3 shows an example of a method for preparing the compound of the general formula (Ia) having [l,3,4]oxadiazole in Ring A from a carboxylic acid compound (a-9) as a starting material by amidation in Step 7-1 and dehydration reaction in Step 7-2, and also shows an example of a method for preparing the compound of the general formula (Ib) having [1 ,2,4]triazole in Ring A by ring reconstruction in Step 7-3. [0126]
  • the amidation in Step 7-1 is performed by the same method as in the aforementioned Step 5-3 and can prepare a compound of the general formula (a-11) from a compound of the general formula (a-9).
  • the dehydration reaction in Step 7-2 varies according to the starting material and is not particularly limited insofar as the conditions are similar to those in this reaction.
  • a known method described in many documents for example, Eur. J. Med. Chem., vol. 42, p. 934, 2007
  • the compound of the general formula (a-11) is stirred in a solvent in the presence of 1.0 to 100.0 equivalents of a dehydration reagent with respect to the compound of the general formula (a-11).
  • the dehydration reagent used varies according to the starting material and is not particularly limited.
  • the dehyration reagent include phosphorus oxychloride, diphosphorus pentoxide, phosphorus pentachloride, thionyl chloride, polyphosphoric acid, triphenylphosphine-carbon tetrachloride and triphenylphosphine- carbon tetrabromide.
  • the solvent used is not particularly limited insofar as it does not inhibit the reaction and allows the starting material to be dissolved therein to a certain extent.
  • the solvent include ether solvents such as tetrahydrofuran, 1,4-dioxane and diethyl ether; halogenated solvents such as methylene chloride, 1,2-dichloroethane and chloroform; polar solvents such as N,N-dimethylformamide, N-methylpyrrolidone and acetonitrile; non-polar solvents such as toluene, benzene and dichlorobenzene; and mixtures thereof.
  • the dehydration reagent may be used as a solvent.
  • the reaction temperature must be a temperature that can complete the reaction without promoting formation of an undesirable byproduct, and is preferably 0 to 200 0 C, for example.
  • the reaction is completed in 1 to 24 hours, and the progress of the reaction can be monitored by a known chromatography technique.
  • An undesirable by-product can be removed by a technique known to a person skilled in the art such as a conventional chromatography technique, extraction or/and crystallization.
  • the conversion of the oxazole ring to a triazole ring in Step 7-3 varies according to the starting material and is not particularly limited insofar as the conditions are similar to those in this reaction.
  • a method known to a person skilled in the art may be used for the reaction.
  • the compound of the general formula (Ia) and 5 to 50 equivalents of a nitrogen source such as ammonia, ammonium salt or formamide with respect to the compound of the general formula (Ia) are stirred in a solvent, for example.
  • the solvent used is not particularly limited insofar as it does not inhibit the reaction and allows the starting material to be dissolved therein to a certain extent.
  • the solvent include organic acids such as acetic acid and trifluoroacetic acid; non-polar solvents such as toluene and benzene; alcohol solvents such as methanol and ethanol; sulfonic acids such as p-toluenesulfonic acid and trifluoromethanesulfonic acid; water; and mixtures thereof.
  • Formamide may optionally be used as a nitrogen atom source and as a solvent.
  • the reaction temperature must be a temperature that can complete the reaction without promoting formation of an undesirable by-product, and is preferably room temperature to 250 0 C, for example. The yield may be improved when the reaction is performed using a tight container.
  • the reaction is completed in 1 to 24 hours, and the progress of the reaction can be monitored by a known chromatography technique.
  • An undesirable by-product can be removed by a technique known to a person skilled in the art such as a conventional chromatography technique, extraction or/and crystallization.
  • the compound of the general formula (f-2) can be prepared from a carboxylic acid compound (f-3) as a starting material through hydrazidation in Step 8-1 and deprotection reaction in Step 8-2.
  • the compound (f-2) can also be directly derived from an ester compound (f-5) as shown in Step 8-3.
  • the amidation in Step 8-1 is performed by the same method as in the aforementioned Step 5-3 and can prepare a compound of the general formula (f-4) from a compound of the general formula (f-3).
  • Step 8-2 The deprotection in Step 8-2 is performed by the same method as in the aforementioned Step 5-4 and can prepare the compound of the general formula (f-2) from the compound of the general formula (f-4).
  • the hydrazidation reaction in Step 8-3 varies according to the starting material and is not particularly limited insofar as the conditions are similar to those in this reaction.
  • An amidation reaction known to a person skilled in the art may be used for the reaction.
  • a method reported in many documents or the like such as described in The Chemical Society of Japan (ed.), Jikken Kagaku Koza (Courses in Experimental Chemistry), 4th edition (vol. 22) Yuki Gosei (Organic Synthesis) [FV], Maruzen Co., Ltd., November 1992, p. 265-267) may be used.
  • a derivative of the compound of the general formula (f-2) having a substituent on the nitrogen atom is obtained using a substituted carbazate (such as benzyl N'- methylhydrazinecarboxylate hydrochloride, CAS No. 880-21-7) instead of a compound of the general formula (f-1).
  • a substituted carbazate such as benzyl N'- methylhydrazinecarboxylate hydrochloride, CAS No. 880-21-7
  • Step 7 can regioselectively introduce a substituent into the [l,2,4]triazole ring of the compound (Ib).
  • R 1 , R 2 , m, n, W and Ring B are as defined above.
  • the above General Preparation Method 4 shows an example of a method for preparing the compound of the general formula (Ic) having [l,2,4]oxadiazole in Ring A from a carboxylic acid compound (a-9) as a starting material by cyclization reaction in Step 9-1.
  • the cyclization reaction in Step 9-1 varies according to the starting material and is not particularly limited insofar as the conditions are similar to those in this reaction.
  • a known method described in many documents may be used for the reaction.
  • the hydroxyguanidine compound (g-1) can be easily prepared by reacting a cyanamide compound with hydroxylamine by a method known to a person skilled in the art (such as described in J. Chem. Soc, Chem. Commun., p. 806, 1970).
  • the above General Preparation Method 5 shows an example of a method for preparing the compound of the general formula (Id) having [l,3,4]oxadiazole in Ring A from a hydrazide compound (a-7) as a starting material by thioamidation in Step 10-1 and cyclization reaction in Step 10-2, and also shows an example of a method for preparing the compound of the general formula (Ie) having [l,3,4]thiadiazole in Ring A from a thioamide compound (a-12) by cyclization reaction in Step 10-3.
  • General Preparation Method 5 further shows an example of a method for preparing the compound of the general formula (If) having [1 ,2,4]triazole in Ring A from a hydrazide compound (a-7) as a starting material by cyclization reaction in Step 10-4.
  • Step 10-1 and the cyclization reaction in Step 10-2 vary according to the starting material and are not particularly limited insofar as the conditions are similar to those in these reactions.
  • Known methods described in many documents such as described in J. Org. Chem., vol. 71, p. 9548, 2006 may be used for the reactions.
  • the isothiocyanate compound (g-2) may be commercially available, or may be easily prepared by a reaction known to a person skilled in the art such as reaction of a commercially available aniline compound with thiocarbonyldiimidazole or thiophosgene.
  • the cyclization reaction in Step 10-3 varies according to the starting material and is not particularly limited insofar as the conditions are similar to those in this reaction.
  • a known method described in many documents (such as described in Rev. Roum. Chim., vol. 50, p. 19, 2005) may be used for the reaction.
  • the cyclization reaction in Step 10-4 varies according to the starting material and is not particularly limited insofar as the conditions are similar to those in this reaction.
  • a known method described in many documents such as described in Eur. J. Med. Chem., vol. 42, p. 152, 2007 may be used for the reaction. [0153]
  • the 2-methylisothiourea compound (g-3) may be commercially available, or may be easily prepared by a reaction known to a person skilled in the art such as reaction of a commercially available thiourea compound with methyl iodide.
  • the bromoacetylation in Step 11-1 varies according to the starting material and is not particularly limited insofar as the conditions are similar to those in this reaction.
  • a known method described in many documents such as described in Bioorg. Med. Chem. Lett., vol. 13, p.
  • the cyclization reaction in Step 11-2 varies according to the starting material and is not particularly limited insofar as the conditions are similar to those in this reaction.
  • a known method described in many documents such as described in Eur. J. Med. Chem., vol. 41, p. 155, 2006) may be used for the reaction.
  • the compound of the formula (g-4) is a known or commercially available compound or is a compound that can be prepared from such a compound by a conventional method.
  • the above General Preparation Method 7 shows an example of a method for preparing the compound of the general formula (Ih) having [l,2,4]oxadiazole in Ring A from a compound (a-8) as a starting material by hydroxyamidine formation in Step 12-1 and cyclization reaction in Step 12-2, and also shows an example of a method for preparing the compound of the general formula (Ii) having [l,2,4]thiadiazole in Ring A from a hydroxyamidine compound (a- 14) as a starting material by cyclization reaction in Step 12-3. [0164]
  • the reaction of forming hydroxyamidine in Step 12-1 varies according to the starting material and is not particularly limited insofar as the conditions are similar to those in this reaction.
  • a known method described in many documents (such as described in Synth. Commun., vol. 26, p. 4351, 1996) may be used for the reaction. [0165]
  • the cyclization reaction in Step 12-2 is achieved by heating a hydroxyamidine compound (a-14) and a 2-methylisothiourea compound (g-3) in a solvent in the presence of a base.
  • Step 12-3 The cyclization reaction in Step 12-3 is achieved by heating a hydroxyamidine compound (a-14) and an isothiocyanate compound (g-2) in a solvent.
  • the compound of the general formula [I] can be prepared according to General Preparation Methods 1 to 7 for the compound of the present invention, and can also be prepared by another method well known to a person skilled in the art.
  • the examples described later will provide reference to these Preparation Methods, and the compound of the general formula [I] can be easily prepared by a method itself known to a person skilled in the art based on these examples.
  • the compound of the general formula [I] or pharmacologically acceptable salt or ester thereof according to the present invention is effective for the treatment of a disease caused by A ⁇ and is excellent in terms of pharmacokinetics, toxicity, stability, absorption and the like.
  • a therapeutic agent for a disease caused by A ⁇ comprising the compound of the formula [I] or pharmacologically acceptable salt or ester thereof according to the present invention as an active ingredient can be prepared by a conventional method.
  • the dosage form include tablets, powders, fine granules, granules, coated tablets, capsules, syrups, troches, inhalants, suppositories, injections, ointments, ophthalmic solutions, ophthalmic ointments, nasal drops, ear drops, cataplasms and lotions.
  • the agent can be prepared by using ingredients typically used such as an excipient, a binder, a lubricant, a colorant and a corrective, and ingredients used where necessary such as a stabilizer, an emulsifier, an absorbefacient, a surfactant, a pH adjuster, a preservative and an antioxidant, and can be prepared by blending ingredients generally used as materials for a pharmaceutical preparation.
  • ingredients typically used such as an excipient, a binder, a lubricant, a colorant and a corrective
  • ingredients used where necessary such as a stabilizer, an emulsifier, an absorbefacient, a surfactant, a pH adjuster, a preservative and an antioxidant, and can be prepared by blending ingredients generally used as materials for a pharmaceutical preparation.
  • ingredients include animal and vegetable oils such as soybean oil, beef tallow and synthetic glyceride; hydrocarbons such as liquid paraffin, squalane and solid paraffin; ester oils such as octyldodecyl myristate and isopropyl myristate; higher alcohols such as cetostearyl alcohol and behenyl alcohol; a silicone resin; silicone oil; surfactants such as polyoxyethylene fatty acid ester, sorbitan fatty acid ester, glycerin fatty acid ester, polyoxyethylene sorbitan fatty acid ester, polyoxyethylene hydrogenated castor oil and a polyoxyethylene-polyoxypropylene block copolymer; water-soluble polymers such as hydroxyethylcellulose, polyacrylic acid, a carboxyvinyl polymer, polyethylene glycol, polyvinylpyrrolidone and methylcellulose; lower alcohols such as ethanol and isopropanol; polyhydric alcohols such as glycerin, propylene
  • excipient used examples include lactose, corn starch, saccharose, glucose, mannitol, sorbitol, crystalline cellulose and silicon dioxide.
  • binder used include polyvinyl alcohol, polyvinyl ether, methylcellulose, ethylcellulose, gum arabic, tragacanth, gelatin, shellac, hydroxypropylmethylcellulose, hydroxypropylcellulose, polyvinylpyrrolidone, a polypropylene glycol-polyoxyethylene block copolymer and meglumine.
  • disintegrant used include starch, agar, gelatin powder, crystalline cellulose, calcium carbonate, sodium bicarbonate, calcium citrate, dextrin, pectin and carboxymethylcellulose calcium.
  • Examples of the lubricant used include magnesium stearate, talc, polyethylene glycol, silica and hydrogenated vegetable oil.
  • Examples of the colorant used include those permitted to be added to pharmaceuticals.
  • Examples of the corrective used include cocoa powder, menthol, empasm, mentha oil, borneol and cinnamon powder.
  • an oral preparation is prepared by adding an active ingredient compound or a salt or ester thereof or a hydrate of the compound or salt or ester, an excipient, and, where necessary, a binder, a disintegrant, a lubricant, a colorant and a corrective, for example, and then forming the mixture into powder, fine granules, granules, tablets, coated tablets or capsules, for example, by a conventional method. It is obvious that tablets or granules may be appropriately coated, for example, sugar coated, where necessary.
  • a syrup or an injection preparation is prepared by adding a pH adjuster, a solubilizer and an isotonizing agent, for example, and a solubilizing agent, a stabilizer and the like where necessary by a conventional method.
  • An external preparation may be prepared by any conventional method without specific limitations.
  • a base material any of various materials usually used for a pharmaceutical, a quasi drug, a cosmetic or the like can be used. Examples of the base material include materials such as animal and vegetable oils, mineral oils, ester oils, waxes, higher alcohols, fatty acids, silicone oils, surfactants, phospholipids, alcohols, polyhydric alcohols, water-soluble polymers, clay minerals and purified water.
  • a pH adjuster, an antioxidant, a chelator, a preservative and fungicide, a colorant, a flavor or the like may be added where necessary. Further, an ingredient having a differentiation inducing effect such as a blood flow enhancer, a bactericide, an antiphlogistic, a cell activator, vitamin, amino acid, a humectant or a keratolytic agent may be blended where necessary.
  • the dose of the therapeutic agent according to the present invention varies according to the degree of symptoms, age, sex, body weight, mode of administration, type of salt and specific type of disease, for example.
  • the compound of the formula [I] or pharmacologically acceptable salt thereof is orally administered to an adult at about 30 ⁇ g to 10 g, preferably 100 ⁇ g to 5 g, and more preferably 100 ⁇ g to 100 mg per day, or is administered to an adult by injection at about 30 ⁇ g to 1 g, preferably 100 ⁇ g to 500 mg, and more preferably 100 ⁇ g to 30 mg per day, in a single dose or several divided doses, respectively.
  • the compound of the formula [I] or pharmacologically acceptable salt or ester thereof according to the present invention may be used in combination with compounds having the following mechanisms.
  • such compounds include cholinesterase inhibitors (e.g., donepezil, huperzine A, tacrine, rivastigmine, galantamine); AMPA receptor antagonists (e.g., 1,2- dihydropyridine compounds such as 3 -(2-cyanophenyl)-5-(2-pyridyl)-l -phenyl- 1,2- dihydropyridin-2-one); NMDA receptor antagonists (e.g., memantine); acetylcholine releasing stimulants (e.g., pramiracetam; aniracetam); calcium channel agonists (e.g., nefiracetam); free radical scavengers (e.g., EGb 761); platelet activating factor antagonists (e.g., EGb 761); platelet aggregation antagonists (e.g., EGb 761, triflusal); insulin sensitizers (e.g., rosiglitazone); per cho
  • angiogenesis inhibitors e.g., paclitaxel
  • immunosuppressants e.g., paclitaxel
  • tubulin antagonists e.g., paclitaxel
  • thromboxane A synthase inhibitors e.g., triflusal
  • antioxidants e.g., idebenone
  • alpha adrenoreceptor antagonists e.g., nicergoline
  • estrogen antagonists e.g., conjugated estrogens, trilostane
  • 3-beta hydroxysteroid dehydrogenase inhibitors e.g., trilostane
  • signal transduction pathway inhibitors e.g., trilostane
  • melatonin receptor agonists e.g., ramelteon
  • immunostimulants e.g., immune globulin, icosapentethyl ester, procaine
  • HIV entry inhibitors e.g., procaine
  • butylcholine esterase inhibitor e.g., bisnorcymserine
  • alpha adrenergic receptor antagonists e.g., nicergoline
  • NO synthase type II inhibitors e.g., arundic acid
  • chelating agents e.g., PBT 2
  • amyloid fibrillogenesis inhibitors e.g., TTP488, PF 4494700
  • serotonin 4 receptor agonists e.g., PRX 03140
  • serotonin 6 receptor antagonists e.g., SB 742457
  • benzodiazepine receptor inverse agonists e.g., radequinil
  • Ca channel antagonists e.g., safinamide
  • nicotinic receptor agonists e.g., ispronicline
  • BACE inhibitor e.g., CTS 21166
  • the above compounds include, for example, donepezil, huperzine A, tacrine, rivastigmine, galantamine, pramiracetam, aniracetam, nefiracetam, EGb 761, rosiglitazone, rasagiline, levacecarnine, celecoxib, 3-(2-cyanophenyl)-5-(2-pyridyl)-l-phenyl- l,2-dihydropyridin-2-one, talampanel, becampanel, memantine, xaliproden, tarenflurbil, tramiprosate, leuprorelin-D, taltirelin, risperidone, cevimeline, modafinil, alosetron, aripiprazole, mifepristone, atorvastatin, propentofylline, choline alfoscerate, FPF 1070 (CAS Number 143637- 01-8), rimon
  • CHF 2060 i.e., N- Heptylcarbamic acid 2,4a,9-trimethyl-2,3,4,4a,9,9a-hexahydro-l ,2-oxazino[6,5-b]indol-6-yl ester-L-tartrate), gedocarnil, terbequinil, HOE 065 (CAS Number 123060-44-6), SL 650102, GR 253035, ALE 26015, SB 271046 (i.e., 5-Chloro-N-(4-methoxy-3-piperazin-l-yl-phenyl)-3- methyl-2-benzothiophenesulfonamide), iAbeta5, SCH 211803 (i.e., Piperidine, l-[l-(3-methyl-2- aminophenyOcarbonylpiperidin ⁇ -ylJ ⁇
  • Cerebrocrast (CAS No. 118790-71-9), NS 626, NS 649 (CAS No. 146828-02-6), U 92032 (CAS No. 142223-92-5), MEM 1003, U 92798, RGH 2716 (CAS No. 134069-68-4), Safinamide (CAS No. 133865-89-1), AZD 0328, MEM 63908, ABT 418 (CAS No. 147402-53-7), ARR 17779, RJR 2403 (CAS No. 538-79-4), TC 2559, A 82695 (CAS No.
  • ABT 107 ABT 560, TC 5619, TAK 070, N- [(lS,2R)-3-(3,5-Difluorophenyl)-l-hydroxy-l-[(5S,6R)-5-methyl-6-(neopentyloxy)morpholin-3- yl]propan-2-yl]acetamide hydrochloride, 6-Fluoro-5-(2-fluoro-5-methylphenyl)-3,4- dihydropyridine, 2- Amino-6- [2-(3 '-methoxybiphenyl-3 -yl)ethyl] -3 ,6-dimethyl-5 ,6- hydroxypyrimidin-4(3H)-one, AZD 1080, ARA 014418, XD 4241, Z 321 (CAS No.
  • Monoclonal antibody 266 duloxetine, escitalopram oxalate, fluoxetine, fluvoxamine maleate, paroxetine, sertraline, dapoxetine, desvenlafaxine, sibutramine, nefazodone, milnacipran, desipramine, duloxetine, and bicifadine.
  • EDC l-Ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride
  • HOBT 1-Hydroxybenzotriazole
  • the organic layer was purified by short silica gel column chromatography (carrier: Wakogel TM C-200 manufactured by Wako Pure Chemic ⁇ al Industries, Ltd.; elution solvent: ethyl acetate). The eluted fraction was concentrated. The resulting residue was triturated with ethyl acetate and tert-butyl methyl ether and dried under reduced pressure to obtain 107.7 g of the title compound. Then, the trituration mother liquor was concentrated. The resulting residue was purified by silica gel column chromatography (carrier: WakogelTM C-200; elution solvent: toluene-ethyl acetate system). The target fraction was concentrated. The resulting residue was triturated with tert-butyl methyl ether and dried under reduced pressure to obtain 12.9 g of the title compound.
  • the property values of the compound are as follows.
  • Tetrakis(triphenylphosphine)palladium (0) (8.5 g) was added to a suspension of 6- bromo-2-methoxy-3-(4-methyl-l H-imidazol- l-yl)pyridine (50 g) and zinc (II) cyanide (35 g) in
  • N-methylpyrrolidone 400 mL
  • the reaction solution was added dropwise to a solution of ice water ( 1.5L) and concentrated aqueous ammonia (150 mL) mixed by stirring.
  • the precipitated powder was filtered.
  • the resulting powder was washed with water and then air-dried overnight to obtain 56.5 g of the title compound.
  • the property values of the compound are as follows.
  • Lithium hydroxide powder (13 g) was added to a suspension of 6-methoxy-5-(4- methyl- lH-imidazol-l-yl)pyridine-2-carbonitrile obtained in Preparation Example 1 (52.4 g) in water (464 mL), and the mixture was heated under reflux for three hours. The reaction solution was left to cool to room temperature. The reaction solution was filtered through celite, and the celite was washed with water (100 mL x 4). Concentrated hydrochloric acid was added to the filtrate under ice-cooling to adjust the pH to 4 to 5. The precipitated powder was collected by filtration. The resulting powder was washed with water and then air-dried for three days to obtain 51.9 g of the title compound.
  • a hydrochloride of the title compound was obtained by the same operation, provided that the hydrogenation reaction was performed in a chloroform-methanol mixed solvent.
  • the property values of the compound are as follows.
  • the target fraction was concentrated.
  • the resulting powder was triturated with diethyl ether-n-hexane and dried under reduced pressure to obtain 1.57 g of the title compound. Then, the mother liquor was concentrated to obtain 858 mg of the title compound.
  • the property values of the compound are as follows.
  • N-bromosuccinimide (543 mg) was added to a solution of 6-(l-ethoxyvinyl)-2- methoxy-3-(4-methyl-lH-imidazol-l-yl)pyridine (791 mg) in THF (15 mL)-water (2 mL) at room temperature, and the mixture was stirred at the same temperature for 15 minutes. A saturated sodium bicarbonate solution and ethyl acetate were added to the reaction solution, and the organic layer was separated. The resulting organic layer was washed with brine and dried over anhydrous magnesium sulfate. Anhydrous magnesium sulfate was removed from the organic layer by filtration. A 4 N solution of hydrogen chloride in ethyl acetate was added to the resulting filtrate. Thereafter, the filtrate was concentrated under reduced pressure to obtain
  • N-Bromosuccinimide (5.66 g) and 2,2'-azobis(isobutyronitrile) (71 mg) were added to a solution of 4-tert-butyl-l-methoxy-2-methylbenzene (5.16 g) in carbon tetrachloride
  • Potassium cyanide (2.96 g) was added to a solution of 2-bromomethyl-4-tert- butyl-1-methoxybenzene (7.78 g) in dimethyl sulfoxide (50 mL), and the mixture was stirred at room temperature for 16 hours. Ice and tert-butyl methyl ether were added to the reaction solution, and the organic layer was separated. The aqueous layer was reextracted with tert- butyl methyl ether. The combined organic layers were sequentially washed with water (twice) and brine, dried over anhydrous magnesium sulfate and then concentrated under reduced pressure.
  • the target fraction was concentrated.
  • the resulting residue was triturated with hexane to obtain 1.90 g of the title compound.
  • the trituration mother liquor was concentrated.
  • the resulting residue was triturated with hexane to obtain 0.47 g of the title compound.
  • the property values of the compound are as follows.
  • l-Chloro-3- iodopropane (1.2 mL) was added dropwise to the solution, and then the reaction solution was gradually heated to room temperature. After ice-cooling the reaction solution, a solution of lithium hexamethyldisilazide in tetrahydrofuran (1.0 M, 4.4 mL) was added to the reaction solution. Then, a lithium diisopropylamide solution prepared from N,N-diisopropylamine (0.6 mL) and a solution of n-butyllithium in hexane (2.69 M, 1.5 mL) was added to the reaction solution. A saturated ammonium chloride solution was added to the reaction solution.
  • the property values of the compound are as follows.
  • Example 3 The compound of Example 3 was obtained by the same method as in Example 2
  • the property values of the compound are as follows.
  • the residue was purified by silica gel column chromatography (carrier: Chromatorex NH; elution solvent: ethyl acetate -> ethyl acetate-methanol) and then further purified by silica gel column chromatography (elution solvent: ethyl acetate-methanol) to obtain 3.01 mg of the title compound.
  • the property values of the title compound are as follows.
  • Methyl iodide (144 ⁇ L) was added to a mixed solution of 2-methoxy-3-(4- methyl- lH-imidazol- 1 -yl)-6-[5-(2-trifluoromethylbenzyl)- 1 H-[ 1 ,2,4]triazol-3-yl] -pyridine obtained in Example 18 (400 mg) and sodium hydride (101 mg) in DMF (6 mL), followed by stirring for two hours. Water was added to the reaction mixture. Then, ethyl acetate was added and the organic layer was separated. The organic layer was washed with brine, dried over anhydrous magnesium sulfate and then filtered. The filtrate was concentrated under reduced pressure.
  • Example 5 (17.3 mg) and N-(2,5-dimethylphenyl)-guanidine (CAS #46049-94-9, 7.38 mg) in DMF (1 mL) was stirred at 100 0 C for 4.5 hours. The reaction solution was cooled to room temperature and then a saturated sodium bicarbonate solution was added, followed by extraction with ethyl acetate three times. The resulting organic layer was dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (carrier: Chromatorex NH; elution solvent: ethyl acetate -> ethyl acetate-methanol) to obtain 1.05 mg of the title compound. The property values of the title compound are as follows.
  • Example 24 The compound of Example 24 was obtained by the same method as in Example 1.
  • reaction solution was stirred at 100°C for three hours and 40 minutes.
  • the reaction solution was left to cool to room temperature.
  • ethyl acetate, water and 1 N hydrochloric acid (1 mL) were added to the reaction solution, and the organic layer was separated.
  • the resulting organic layer was sequentially washed with half-saturated brine and brine, dried over anhydrous magnesium sulfate and then concentrated under reduced pressure.
  • the neuronal cell suspension was diluted with the medium and then plated in a volume of 100 ⁇ l/well at an initial cell density of 5 x 10 5 cells/cm 2 in a 96-well polystyrene culture plate pre- coated with poly-L or D-lysine (Falcon Cat #35-3075, Becton Dickinson Labware, Franklin Lakes, NJ, USA coated with poly-L-lysine using the method shown below, or BIOCO ATTM cell environments Poly-D-lysine cell ware 96-well plate, Cat #35-6461, Becton Dickinson Labware, Franklin Lakes, NJ, USA). Poly-L-lysine coating was carried out as follows.
  • the drug was added to the culture plate on Day 4 of culture as follows.
  • the total amount of the medium was removed from the wells, and 180 ⁇ l/well of Neurobasal medium not containing 2-ME and containing 2% B-27 (Neurobasal/B27) was added thereto.
  • a solution of the test compound in dimethyl sulfoxide (hereinafter abbreviated as DMSO) was diluted with Neurobasal/B27 to a concentration 10-fold higher than the final concentration. 20 ⁇ l/well of the dilution was added to and sufficiently mixed with the medium. The final DMSO concentration was 1% or less. Only DMSO was added to the control group. [0338] Sampling
  • the cells were cultured for three days after addition of the compound, and the total amount of the medium was collected. The resulting medium was used as an ELISA sample. [0339] Evaluation of cell survival
  • MTT MTT assay
  • 100 ⁇ l/well of a pre- warmed medium was added to the wells.
  • 8 ⁇ l/well of a solution of 8 mg/mL of MTT (SIGM A M2128, St. Louis, MO, USA) in D-PBS(-) (Dulbecco's phosphate buffered Saline, SIGMA D8537, St. Louis, MO, USA) was added to the wells.
  • the 96-well polystyrene culture plate was incubated in an incubator at 37°C in 5% CO 2 -95% air for 20 minutes.
  • the MTT lysis buffer was prepared as follows. 100 g of SDS (sodium dodecyl sulfate (sodium lauryl sulfate), WAKO 191-07145, Osaka, Japan) was dissolved in a mixed solution of 250 mL of N,N-dimethylformamide (WAKO 045-02916, Osaka, Japan) with 250 mL of distilled water. 350 ⁇ l each of concentrated hydrochloric acid and acetic acid were further added to the solution to allow the solution to have a final pH of about 4.7.
  • % of CTRL ((A550_sample - A550_bkg)/(A550_CTRL - bkg)) x 100 (A550_sample: absorbance at 550 run of sample well, A550_bkg: absorbance at 550 nm of background well, A550 CTRL: absorbance at 550 nm of control group well) [0340]
  • a ⁇ ELISA 5 Human/Rat ⁇ Amyloid (42) ELISA Kit Wako (#290-62601) from Wako Pure Chemical Industries, Ltd. or Human Amyloid beta (1-42) Assay Kit (#27711) from IBL Co., Ltd. was used.
  • a ⁇ ELISA was carried out according to the protocols recommended by the manufacturers (methods described in the attached documents). However, the A ⁇ calibration curve was created using beta-amyloid peptide 1 -42, rat (Calbiochem, # 171596
  • the compound of the general formula [I] or pharmacologically acceptable salt thereof according to the present invention have an A ⁇ 42 production reducing effect.
  • the present invention can particularly provide a therapeutic agent for a neurodegenerative disease caused by A ⁇ such as Alzheimer's disease or Down's syndrome.
  • the compound of the general formula [I] according to the present invention has an A ⁇ production reducing effect, and thus is particularly useful as a therapeutic agent for a neurodegenerative disease caused by A ⁇ such as Alzheimer's disease or Down's syndrome.

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Psychiatry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La présente invention concerne un composé représenté par la formule (I) ou un sel ou un ester pharmacologiquement acceptable de ce composé, dans lequel l'anneau A représente un groupe triazolyle ou similaire qui peut être substitué, l'anneau B représente un groupe phényle ou similaire qui peut être substitué, X1 représente une liaison simple ou similaire, R1 et R2 représentent chacun un groupe alkyle C1-6 ou similaire, m représente un entier compris entre 0 et 3, et n représente un entier compris entre 0 et 2. Ce composé est efficace en tant qu'agent thérapeutique pour une maladie provoquée par la protéine amyloïde bêta.
PCT/JP2010/053370 2009-02-26 2010-02-24 Composé arylimidazole et leur utilisation en tant qu'inhibiteurs de production de la protéine amyloïde bêta WO2010098488A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US15577809P 2009-02-26 2009-02-26
JP2009043434A JP2012051807A (ja) 2009-02-26 2009-02-26 アリールイミダゾール化合物
JP2009-043434 2009-02-26
US61/155,778 2009-02-26

Publications (1)

Publication Number Publication Date
WO2010098488A1 true WO2010098488A1 (fr) 2010-09-02

Family

ID=42313842

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2010/053370 WO2010098488A1 (fr) 2009-02-26 2010-02-24 Composé arylimidazole et leur utilisation en tant qu'inhibiteurs de production de la protéine amyloïde bêta

Country Status (4)

Country Link
JP (1) JP2012051807A (fr)
AR (1) AR075607A1 (fr)
TW (1) TW201035076A (fr)
WO (1) WO2010098488A1 (fr)

Cited By (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8697673B2 (en) 2011-03-31 2014-04-15 Pfizer Inc. Bicyclic pyridinones
US8754100B2 (en) 2009-02-26 2014-06-17 Eisai R&D Management Co., Ltd. Nitrogen-containing fused heterocyclic compounds and their use as beta amyloid production inhibitors
US8822699B2 (en) 2010-09-02 2014-09-02 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof
US8835482B2 (en) 2009-05-07 2014-09-16 Janssen Pharmaceuticals, Inc. Substituted indazole and aza-indazole derivatives as gamma secretase modulators
US8884017B2 (en) 2001-12-27 2014-11-11 Bayer Intellectual Property Gmbh 2-heteroarylcarboxylic acid amides
US8916564B2 (en) 2012-09-21 2014-12-23 Pfizer Inc. Substituted pyrido[1,2-a]pyrazines for the treatment of neurodegenerative and neurological disorders
US8946266B2 (en) 2009-07-15 2015-02-03 Janssen Pharmaceuticals, Inc. Substituted triazole and imidazole derivatives as gamma secretase modulators
US8946426B2 (en) 2009-02-06 2015-02-03 Janssen Pharmaceuticals, Inc. Substituted bicyclic heterocyclic compounds as gamma secretase modulators
US8987276B2 (en) 2011-03-24 2015-03-24 Janssen Pharmaceuticals, Inc. Substituted triazolyl piperazine and triazolyl piperidine derivatives as gamma secretase modulators
US9079886B2 (en) 2010-01-15 2015-07-14 Janssen Pharmaceuticals, Inc. Substituted triazole derivatives as gamma secretase modulators
US9108961B2 (en) 2010-05-17 2015-08-18 Forum Pharmaceuticals, Inc. Crystalline form of (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide hydrochloride
US9115143B2 (en) 2011-07-15 2015-08-25 Janssen Pharmaceuticals, Inc. Substituted indole derivatives as gamma secretase modulators
US9181245B2 (en) 2012-05-16 2015-11-10 Janssen Pharmaceuticals, Inc. Substituted pyrido[1,2-a]pyrazines and substituted pyrido[1,2-a][1,4]diazepines for the treatment of (inter alia) Alzheimer's disease
US9365552B2 (en) 2010-03-19 2016-06-14 Novartis Ag Pyridine and pyrazine derivative for the treatment of CF
US9403815B2 (en) 2010-06-24 2016-08-02 The Regents Of The University Of California Compounds and uses thereof in modulating levels of various amyloid beta peptide alloforms
US9585877B2 (en) 2012-05-08 2017-03-07 Forum Pharmaceuticals, Inc. Methods of maintaining, treating or improving cognitive function
US9765073B2 (en) 2015-02-03 2017-09-19 Pfizer Inc. Cyclopropabenzofuranyl pyridopyrazinediones
US9938263B2 (en) 2013-03-12 2018-04-10 The General Hospital Corporation Gamma-secretase modulators
US10112943B2 (en) 2012-12-20 2018-10-30 Janssen Pharmaceutica Nv Substituted imidazoles as gamma secretase modulators
US10246454B2 (en) 2013-01-17 2019-04-02 Janssen Pharmaceutica Nv Substituted 3,4-dihydro-2H-pyrido[1,2-a]pyrazine-1,6-diones as gamma secretase modulators
US10472346B2 (en) 2014-10-31 2019-11-12 The General Hospital Corporation Potent gamma-secretase modulators
US10818850B2 (en) 2017-12-22 2020-10-27 Samsung Display Co., Ltd. Organic electroluminescence device and compound including nitrogen for organic electroluminescence device
US11447478B2 (en) 2013-04-11 2022-09-20 Hoffmann-La Roche Inc. BACE1 inhibitors
US11718593B2 (en) 2018-05-17 2023-08-08 Southern Research Institute 2,5-aryl-thiazole analogs for the treatment of neurodegenerative diseases
US11905258B2 (en) 2018-02-21 2024-02-20 Southern Research Institute 2-aminoaryl-5-aryloxazole analogs for the treatment of neurodegenerative diseases

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9702490B2 (en) 2013-04-30 2017-07-11 Corning Incorporated Sealing method for silicon carbide parts used at high temperatures

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002068417A2 (fr) * 2001-02-21 2002-09-06 Nps Pharmaceuticals, Inc. Composes heteropolycycliques et leur utilisations en tant qu'antagonistes des recepteurs metabotropiques du glutamate
WO2004110350A2 (fr) * 2003-05-14 2004-12-23 Torreypines Therapeutics, Inc. Composes et leurs utilisations pour la modulation de l'amyloide-beta
DE102004061750A1 (de) 2004-12-22 2006-07-06 Bayer Healthcare Ag Heteroaryl-substituierte Pyrazoline
WO2007139149A1 (fr) 2006-05-31 2007-12-06 Eisai R & D Management Co., Ltd. Composé pour réactif biologique
EP1992618A1 (fr) * 2006-03-09 2008-11-19 Eisai R&D Management Co., Ltd. Dérivé polycyclique de cinnamide
WO2008156580A1 (fr) * 2007-06-13 2008-12-24 Merck & Co., Inc. Dérivés du triazole destinés au traitement de la maladie d'alzheimer et d'états associés

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002068417A2 (fr) * 2001-02-21 2002-09-06 Nps Pharmaceuticals, Inc. Composes heteropolycycliques et leur utilisations en tant qu'antagonistes des recepteurs metabotropiques du glutamate
WO2004110350A2 (fr) * 2003-05-14 2004-12-23 Torreypines Therapeutics, Inc. Composes et leurs utilisations pour la modulation de l'amyloide-beta
DE102004061750A1 (de) 2004-12-22 2006-07-06 Bayer Healthcare Ag Heteroaryl-substituierte Pyrazoline
EP1992618A1 (fr) * 2006-03-09 2008-11-19 Eisai R&D Management Co., Ltd. Dérivé polycyclique de cinnamide
WO2007139149A1 (fr) 2006-05-31 2007-12-06 Eisai R & D Management Co., Ltd. Composé pour réactif biologique
WO2008156580A1 (fr) * 2007-06-13 2008-12-24 Merck & Co., Inc. Dérivés du triazole destinés au traitement de la maladie d'alzheimer et d'états associés

Non-Patent Citations (108)

* Cited by examiner, † Cited by third party
Title
"Courses in Experimental Chemistry", vol. 19, article "The Chemical Society of Japan"
"Courses in Experimental Chemistry", vol. 20, article "The Chemical Society of Japan"
"Courses in Experimental Chemistry", vol. 22, article "The Chemical Society of Japan"
A. SUZUKI, CHEM. REV., vol. 95, 1995, pages 2457
ASSINI A: "Plasma levels of amyloid ?-prolein 42 are increased in women with mild cognitive impariment", NEUROLOGY, vol. 63, no. 5, 14 September 2004 (2004-09-14), pages 828 - 831
ATWOOD CS: "Cerebrovascular requirement for sealant, anti-coagulant and remodeling molecules that allow for the maintenance of vascular integrity and blood supply", BRAIN RESEARCH REVIEWS, vol. 43, no. 1, September 2003 (2003-09-01), pages 164 - 78
BARELLI H: "Characterization of new polyclonal antibodies specific for 40 and 42 amino acid-long amyloid ? peptides: their use to examine the cell biology of presenilins and the immunohistochemistry of sporadic Alzheimer's disease and cerebral amyloid angiopathy cases", MOLECULAR MEDICINE, vol. 3, no. 10, October 1997 (1997-10-01), pages 695 - 707
BARRACHINA M: "Amyloid-? deposition in the cerebral cortex in Dementia with Lewy bodies is accompanied by a relative increase in A?PP mRNA isoforms containing the Kunitz protease inhibitor", NEUROCHEMISTRY INTERNATIONAL, vol. 6, no. 3, 4 February 2005 (2005-02-04), pages 253 - 260
BARRACHINA M: "Amyloid-P deposition in the cerebral cortex in Dementia with Lewy bodies is accompanied by a relative increase in A?PP mRNA isofonns containing the Kunitz protease inhibitor", NEUROCHEMISTRY INTERNATIONAL, vol. 6, no. 3, 4 February 2005 (2005-02-04), pages 253 - 260
BEST JD: "In vivo characterization of A? (40) changes in brain and cerebrospinal fluid using the novel y-secretase inhibitor N-[cis-4-[(4-chlorophenyl)sulfonyl]-4-(2,5 -difluorophenyl)cyclohexyl]-1,1,1 1-trifluoromethanesulphonlamide (MK-560) in the rat", THE JOURNAL OF PHARMACOLOGY AND EXPERIMANTAL THERAPEUTICS, vol. 7, no. 2, 31 May 2006 (2006-05-31), pages 786 - 790
BEST JD: "The novel y-secretase inhibitor N-[cis-4-[(4-chlorophenyl)sulfonyl]-4-(2,5=difluorophenyl)cyclohexyl]-1,1,1-trifluoromethanesulphonlamide (MK-560) reduces amylid plaque deposition without evidence notch-related pathology in the Tg2576 mouse", THE JOURNAL OF PHARMACOLOGY AND EXPERIMANTAL THERAPEUTICS, vol. 320, no. 2, February 2007 (2007-02-01), pages 552 - 558
BIOORG. MED. CHEM. LETT., vol. 13, 2003, pages 2059
BLASS JP: "Brain metabolism and brain disease: Is metabolic deficiency theproximate cause of Alzheimer dementia", JOUMAL OF NEUROSCIENCE RESEARCH, vol. 66, no. 5, 1 December 2001 (2001-12-01), pages 851 - 856
CALHOUN ME: "Neuronal overexpression of mutant amyloid precursor protein results in prominent deposition of cerebrovascular amyloid", PROCEEDING NATIONAL ACADEMY OF SCIENCE USA, vol. 96, no. 24, 23 November 1999 (1999-11-23), pages 14088 - 14093
CRAS P: "Presenile Alzheimer dementia characterized by amyloid angiopathy and large amyloid core type senile plaques in the APP 692Ala -> Gly mutation", ACTA NEUROPATHOLOGICA (BERL), vol. 96, no. 3, September 1998 (1998-09-01), pages 253 - 260
CROOK R: "A variant of Alzheimer's disease with spastic pararesis and unusual plaques due to deletion of exon 9 of presenilin 1", NATURE MEDICINE, vol. 4, no. 4, April 1998 (1998-04-01), pages 452 - 455
D.D. DAVEY ET AL., J. MED. CHCM., vol. 34, 1991, pages 2671 - 2677
DATABASE REGISTRY [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 1 March 2009 (2009-03-01), XP002592076, Database accession no. 1113118-01-6 *
DATABASE REGISTRY [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 13 June 2008 (2008-06-13), XP002592073, Database accession no. 1027938-27-7 *
DATABASE REGISTRY [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 26 February 2009 (2009-02-26), XP002592075, Database accession no. 1112297-08-1 *
DATABASE REGISTRY [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 6 June 2008 (2008-06-06), XP002592074, Database accession no. 1026025-89-7 *
DE MEYER GR: "Platelet phagocytosis and processing of ?-amyloid precursor protein as a mechanism of macrophage activation in atherosclerosis", CIRCULATION RESERACH, vol. 90, no. 11, 14 June 2002 (2002-06-14), pages 1197 - 1204
DERMAUT B: "Cerebral amyloid angiopathy is a pathogenic lesion in Alzheimer's Disease due to a novel presenilm-1 mutation", BRAIN, vol. 4, no. 12, 12 December 2001 (2001-12-12), pages 2383 - 2392
DUINEN SG: "Hereditary cerebral hemorrhage with amyloidosis in patients of Dutch origin is related to Alzheimer disease", PROCEEDING NATIONAL ACADEMY OF SCIENCE USA, vol. 84, no. 16, August 1987 (1987-08-01), pages 5991 - 5994
EUR. J. MED. CHEM., vol. 41, 2006, pages 155
EUR. J. MED. CHEM., vol. 42, 2007, pages 152
EUR. J. MED. CHEM., vol. 42, 2007, pages 934
EVERT BO: "Inflammatory genes are upreglulated in expanded ataxin-3-expressing cell lines and spinocerrebellar ataxia type 3 brains", THE JOURNAL OF NEUROSCIENCE, vol. 21, no. 15, 1 August 2001 (2001-08-01), pages 5389 - 5396
EVIN G: "Alternative transcripts of presenilin-1 associated with frontotemporal dementia", NEUROREPORT, vol. 13, no. 5, 16 April 2002 (2002-04-16), pages 719 - 723
FORMAN MS: "Differential effects of the Swedish mutant amyloid precursor protein on ?-amyloid accumulation and secretion in neurons and nonneuronal cells", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 272, no. 51, 19 December 1997 (1997-12-19), pages 32247 - 32253
FORMAN MS: "Diiferential effects of the swedish mutant amyloid precursor protein on ?-amyloid accumulation and secretion in neurons and nonneuronal cells", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 272, no. 51, 19 December 1997 (1997-12-19), pages 32247 - 32253
GATTAZ WF: "Platelet phospholipase A2 activity in Alzheimer's disease and mild cognitive impainment", JOURNAL OF NEURAL TRANSMISSION, vol. 111, no. 5, May 2004 (2004-05-01), pages 591 - 601
GEHRMANN J: "Amyloid precursor protein (APP) expression in multiple sclerosis lesions", GLIA, vol. 15, no. 2, October 1995 (1995-10-01), pages 141 - 51
GIASSON BI: "Interactions of amyloidogenic proteins", NEUROMOLECULAR MEDICINE, vol. 4, no. 1-2, 2003, pages 49 - 58
GITTER. BD: "Stereoselective inhibition of amyloid beta peptide secretion by LY450139, a novel functional gamma secretase inhibitor", NEUROLOGY OF AGING, vol. 25, no. 2, 2004, pages 571
GLENNER GG: "Alzheimer's disease; initial report of the purification and characterization of a novel cerebrovascular amyloid protein", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 120, no. 3, 16 May 1984 (1984-05-16), pages 885 - 890
GLENNER GQ: "Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 120, no. 3, 16 May 1984 (1984-05-16), pages 885 - 890
GOURAS GK: "Intraneuronal A?42 accumulation in human brain", AMERICAN JOURNAL OF PATHOLOGY, vol. 156, no. 1, January 2000 (2000-01-01), pages 15 - 20
GOURAS GK: "Intraneuronal Ap42 accumulation in human brain", AMERICAN JOURNAL OF PATHOLOGY, vol. 156, no. 1, January 2000 (2000-01-01), pages 15 - 20
HAMILTON RL: "Alzheimer disease pathology in amyotrophic lateral sclerosis", ACTA NEUROPATHOLOGICA, vol. 7, no. 6, 10 June 2004 (2004-06-10), pages 515 - 522
HAYASHI Y: "Evidence for presenilin-1 involvement in amyloid angiopathy in the Alzheimer's disease-affected brain", BRAIN RESEARCH, vol. 789, no. 2, 13 April 1998 (1998-04-13), pages 307 - 314
HERZIG MC: "A? is tatgeted to the vasculature in a mouse model of hereditary cerebral hemorrhage with amyloidosis", NATURE NEUROSCIENCE, vol. 7, no. 9, September 2004 (2004-09-01), pages 954 - 960
ITO H: "Demonstration of ? amyloid protein- containing neurofibrillary tangles in parkinsonism-dementia complex on Guam", NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY, vol. 17, no. 5, October 1991 (1991-10-01), pages 365 - 373
J. CHEM. SOC., CHEM. COMMUN., 1970, pages 806
J. MASS SPECTRUM. SOC. JPN., vol. 51, no. 5, 2003, pages 492 - 498
J. ORG. CHEM., vol. 71, 2006, pages 9548
J.K. STILLE, ANGEW. CHEM. INT ED. ENGL., vol. 25, 1986, pages 508
J.K. STILLE, ANGEW. CHEM. INT. ED. ENGL., vol. 25, 1986, pages 508
J.P. COLLMAN ET AL., ORG. LETTERS., vol. 2, 2000, pages 1233 - 1236
JARRETT JT: "The carboxy terminus of the ? amyloid protein is critical for the seeding of amyloid formation: Implications for the pathogenesis of Alzheimer's disease", BIOCHEMISTRY, vol. 32, no. 18, 11 May 1993 (1993-05-11), pages 4693 - 4697
JARRETT JT: "The carboxy terminus of the ? amyloid protein is critical for the seeding of amyloid formation: Implications for the pathogenesis of Alzheimers' disease", BIOCHEMISTRY, vol. 32, no. 18, 1993, pages 4693 - 4697
JIN LW: "Intracellular accumulation of amyloidogenic fragments of amyloid-? precursor protein in neurons with Niemann-Pick type C defects is associated with endosomal abnormalities", AMERICAN JOURNAL OF PATHOLOGY, vol. 4, no. 3, 16 March 2004 (2004-03-16), pages 975 - 985
KIRKITADZE MD: "Paradigm shifts in Alzheimer's disease and other neurodegenerative disorders: the emerging role of oligomeric assemblies", JOURNAL OF NEUROSCIENCE RESEARCH, vol. 69, no. 5, 1 September 2002 (2002-09-01), pages 567 - 577
KLEIN WL: "Alzheimer's disease-affected brain: Presence of oligomeric AØ ligands (ADDLs) suggests a molecular basis for reversible memory loss", PROCEEDING OF THE NATIONAL ACADEMY OF SCIENCE USA, vol. 100, no. 18, 2 September 2003 (2003-09-02), pages 10417 - 10422
KOISTINAHO M: "?-amyloid precursor protein transgenic mice that harbor diffuse A? deposits but do not form plaques show increased ischemic vulnerability: Role of inflammation", PROCEEDING NATIONAL ACADEMY OF SCIENCE USA, vol. 99, no. 3, 5 February 2002 (2002-02-05), pages 1610 - 1615
LANZ TA: "Concentration-dependent modulation of amyloid-? in vivo and in vitro using the ?-secretase inhibitor, LY-450139", THE JOURNAL OF PHARMACOLOGY AND EXPERIMANTAL THERAPEUTICS, vol. 319, no. 2, November 2006 (2006-11-01), pages 924 - 933
LANZ TA: "Studies of A? pharmacodynamics in the brain, cerebrospinal fluid, and plasma in young (plaque-free) Tg2576 mice using the y-secretase inhibitor N2-[(2S)-2-(3,5=difluorophenyl)-2-hydroxyethanoyl]-N1-[(7S)-5-methyl-6-oxo-6,7-dihydro-5H-dibenzo[b,d]azepin-7-yl]-L-alaninamide (LY-411575)", THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, vol. 309, no. 1, April 2004 (2004-04-01), pages 49 - 55
LAWS SM: "Association between the presenilin-1 mutation Glu318Gly and complaints of memory impairment", NEUROBIOLOGY OF AGING, vol. 23, no. 1, January 2002 (2002-01-01), pages 55 - 58
LEVY E: "Mutation of the Alzheimer's disease amyloid gene in hereditary cerebral hemorrhage, Dutch type", SCIENCE, vol. 248, no. 4959, 1 June 1990 (1990-06-01), pages 1124 - 1126
LOWENSON JD: "Protein aging: Extracellular amyloid formation and intracellular repair", TRENDS IN CARDIOVASCULAR MEDICINE, vol. 4, no. 1, 1994, pages 3 - 8
MANN DM: "Deposition of amyloid (A4) protein within the brains of persons with dementing disorders other than Alzheimer's disease and Down's syndrome", NEUROSCIENCE LETTERS, vol. 109, no. 1-2, 5 February 1990 (1990-02-05), pages 68 - 75
MASLIAH E: "?-amyloid peptides enhance a-synuclein accumulation and neuronal deficits in a transgenic mouse model linking Alzheimer's disease and Parkinson's disease", PROCEEDING NATIONAL ACADEMY OF SCIENCE USA, vol. 98, no. 21, 9 October 2001 (2001-10-09), pages 12245 - 12250
MASTERS CL: "Amyloid plaque core protein in Alzheimer disease and Down syndrome", PROCEEDING NATIONAL ACADEMY OF SCIENCE USA, vol. 2, no. 12, 8 June 1985 (1985-06-08), pages 4245 - 4249
MASTERS CL: "Amyloid plaque core protein in Alzheimer disease and Down syndrome", PROCEEDING OF THE NATIONAL ACADEMY OF SCIENCE USA, vol. 82, no. 12, June 1985 (1985-06-01), pages 4245 - 4249
MATSUBARA-TSUTSUI M: "Molecular evidence of presenilin 1 mutation in familial early onset dementia", AMERICAN JOURNAL OF MEDICAL GENETICS, vol. 114, no. 3, 8 April 2002 (2002-04-08), pages 292 - 298
MORAN PM: "Age-related learning deficits in transgenic mice expressing the 751-amino acid isoform of human (?-amyloid precursor protein", PROCEEDING NATIONAL ACADEMY OF SCIENCE USA, vol. 92, no. 12, 6 June 1995 (1995-06-06), pages 5341 - 5345
MORGAN D: "A? peptide vaccination prevents memory loss in an animal model of Alzheimer's disease", NATURE, vol. 408, no. 6815, 21 December 2000 (2000-12-21), pages 982 - 985
NITSCH RM: "Antibodies against ?-amyloid slow cognitive decline in Alzheimer's disease", NEURON, vol. 38, 22 May 2003 (2003-05-22), pages 547 - 554
NITSCH RM: "Antibodies against ?-amyloid slow cognitive decline in Alzheimer's disease", NEURON, vol. 38, no. 4, 22 May 2003 (2003-05-22), pages 547 - 554
O'RIORDAN S: "Presenilin-1 mutation (E280G), spastic paraparesis, and cranial MRI white-matter abnormalities", NEUROLOGY, vol. 59, no. 7, 8 October 2002 (2002-10-08), pages 1108 - 1110
PRIMAVERA J: "Brain accumulation of amyloid-? in Non-Alzheimer Neurodegeneration", JOURNAL OF ALZHEIMER'S DISEASE, vol. 1, no. 3, October 1999 (1999-10-01), pages 183 - 193
PRIMAVERA J: "Brain accumulation of amyloid-P in Non-Alzheimer Neurodegeneration", JOURNAL OF ALZHEIMER'S DISEASE, vol. 1, no. 3, October 1999 (1999-10-01), pages 183 - 193
PROCEEDING NATIONAL ACADEMY OF SCIENCE USA, vol. 100, no. 18, 2 September 2003 (2003-09-02), pages 10417 - 10422
REV. ROUM. CHIM., vol. 50, 2005, pages 19
REYNOLDS WF: "Myeloperoxidase polymorphism is associated with gender specific risk for Alzheimer's disease", EXPERIMENTAL NEUROLOGY, vol. 5, no. 1, 15 January 1999 (1999-01-15), pages 31 - 41
ROSSO SM: "Coexistent tau andamyloid pathology in hereditary frontotemporal dementia with tau mutations", ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, vol. 920, 2000, pages 115 - 119
SADOWSKI M: "Links between the pathology of Alzheimer's disease and vascular dementia", NEUROCHEMICAL RESEARCH, vol. 29, no. 6, June 2004 (2004-06-01), pages 1257 - 1266
SASAKI S: "Immunoreactivity of ?-amyloid precursor protein in amyotrophic lateral sclerosis", ACTA NEUROPATHOLOGICA (BERL), vol. 7, no. 5, 9 May 1999 (1999-05-09), pages 463 - 468
SCHEUNER D: "Secreted amyloid ?-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease", NATURE MEDICINE, vol. 2, no. 8, August 1996 (1996-08-01), pages 864 - 870
SCHEUNER D: "Secreted amyloid ?-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin I and 2 and APP mutations linked to familial Alzheimer's disease", NATURE MEDICINE, vol. 2, no. 8, August 1996 (1996-08-01), pages 864 - 870
SCHMIDT ML: "Amyloid plaques in Guam amyotrophic lateral sclerosis/ parkinsonism-dementia. complex contain species of A? similar to those found in the amyloid plaques of Alzheimer's disease and pathological aging", ACTA NEUROPATHOLOGICA (BERL), vol. 5, no. 2, 9 February 1998 (1998-02-09), pages 117 - 122
SHEARMAN MS: "Catalytic Site-Directed 1-Secretase Complex Inhibitors Do Not Discriminate Pharmacologically between Notch S3 and ?-APP Clevages", BIOCHEMISTRY, vol. 42, no. 24, 24 June 2003 (2003-06-24), pages 7580 - 7586
SHEARMAN MS: "L-685, 458, an Aspartyl Protease Transition State Mimic, Is a Potent Inhibitor of Amyloid ?-Protein Precursor y-Secretase Activity", BIOCHEMISTRY, vol. 39, no. 30, 1 August 2000 (2000-08-01), pages 8698 - 8704
SIEMERS ER: "Effects of a.y-secretase inhibitor in a randamized study of patients with Alzheimer disease", NEUROLOGY, vol. 66, 2006, pages 602 - 604
SILVERBERG GD: "Alzheimer's disease, normal-pressure hydrocephalus, and senescent changes in CSF circulatory physiology: a hypothesis", LANCET NEUROLOGY, vol. 2, no. 8, August 2003 (2003-08-01), pages 506 - 511
SINGLETON AB: "Pathology of early-onset Alzheimer's disease cases bearing the Thr113-114ins presenilin-1 mutation", BRAIN, vol. 123, December 2000 (2000-12-01), pages 2467 - 2474
SMITH DH: "Protein accumulation in traumatic brain injury", NEUROMOLECULAR MEDICINE, vol. 4, no. 1-2, 2003, pages 59 - 72
SMITH MJ: "Variable phenotype of Alzheimer's disease with spastic paraparesis", ANNALS OF NEUROLOGY, vol. 49, no. 1, 2001, pages 125 - 129
SYNTH. COMMUN., vol. 26, 1996, pages 4351
T. GREENE ET AL.: "Protective Groups in Organic Synthesis", 1981, JOHN WILEY & SONS, INC.
TAMAOKAA: "Increased amyloid p protein in the skin of patients with amyotrophic lateral sclerosis", JOURNAL OF NEUROLOGY, vol. 247, no. 8, August 2000 (2000-08-01), pages 633 - 635
TELLER JK: "Presence of soluble amyloid ?-peptide precedes amyloid plaque formation in Down's syndrome", NATURE MEDICINE, vol. 2, no. 1, January 1996 (1996-01-01), pages 93 - 95
TOKUDA T: "Plasma levels of amyloid ? proteins A?1-40 and A? 1-42 (43) are elevated in Down's syndrome", ANNALS OF NEUROLOGY, vol. 1, no. 2, 4 February 1997 (1997-02-04), pages 271 - 273
TOLNAY M: "Low amyloid (A?) plaque load and relative predominance of diffuse plaques distinguish argyrophilic grain disease from Alzheimer's disease", NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY, no. 4, 25 August 1999 (1999-08-25), pages 295 - 305
TURNER BJ: "Brain ?-amyloidaccumulation in transgenic mice expressing mutant superoxide dismutase 1", NEUROCHEMICAL RESEARCH, vol. 29, no. 12, December 2004 (2004-12-01), pages 2281 - 2286
VAUCHER E: "Object recognition memory and cholinergic parameters in mice expressing human presenilin 1 transgenes", EXPERIMENTAL NEUROLOGY, vol. 175, no. 2, June 2002 (2002-06-01), pages 398 - 406
WELLER RO: "Cerebral amyloid angiopathy: Accumulation of A? in interstitial fluid drainage pathways in Alzheimer's disease", ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, vol. 903, April 2000 (2000-04-01), pages 110 - 117
WELLER RO: "Cerebrovascular disease is a major factor in the failure of elimination of A? from the aging human brain", ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, vol. 977, November 2002 (2002-11-01), pages 162 - 168
WELLER RO: "Pathology of cerebrospinal fluid and interstitial fluid of the CNS: Significance for Alzheimer's disease, prion disorders and multiple sclerosis", JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY, vol. 7, no. 10, 5 October 1998 (1998-10-05), pages 885 - 894
WONG GT: "Chronic treatment with the y-secretase inhibitor LY-411, 575 inhibits p-amyloid peptide production and alters lymphopoiesis and intestinal cell differentiation", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 279, no. 13, 26 March 2004 (2004-03-26), pages 12876 - 12882
YASUHARA O: "Accumulation of amyloid precursor protein in brain lesions of patients with Pick disease", NEUROSCIENCE LETTERS, vol. 171, no. 1-2, 25 April 1994 (1994-04-25), pages 63 - 66
YOW HY: "A role for cerebrovascular disease in determining the pattern of ?-amyloid deposition in Alzheimer's disease", NEUROLOGY AND APPLIED NEUROBIOLOGY, vol. 28, 2002, pages 149
YUKI GOSEI: "(Organic Synthesis) [IV]", November 1992, MARUZEN CO., LTD., pages: 12 - 13
YUKI GOSEI: "(Organic Synthesis) [IV]", November 1992, MARUZEN CO., LTD., pages: 137 - 144
YUKI GOSEI: "(Organic Synthesis) [IV]", November 1992, MARUZEN CO., LTD., pages: 265 - 267
YUKI GOSEI: "Organic Synthesis) [1]", November 1992, MARUZEN CO., LTD., pages: 450 - 453
YUKI GOSEI: "Organic Synthesis) [IV]", November 1992, MARUZEN CO., LTD., pages: 279 - 280
ZHANG F: "Increased susceptibility to ischemic brain damage in transgenic mice overexpressing the amyloid precursor protein", THE JOURNAL OF NEUROSCIENCE, vol. 17, no. 20, 15 October 1997 (1997-10-15), pages 7655 - 7661

Cited By (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8884017B2 (en) 2001-12-27 2014-11-11 Bayer Intellectual Property Gmbh 2-heteroarylcarboxylic acid amides
US8946426B2 (en) 2009-02-06 2015-02-03 Janssen Pharmaceuticals, Inc. Substituted bicyclic heterocyclic compounds as gamma secretase modulators
US8754100B2 (en) 2009-02-26 2014-06-17 Eisai R&D Management Co., Ltd. Nitrogen-containing fused heterocyclic compounds and their use as beta amyloid production inhibitors
US8835482B2 (en) 2009-05-07 2014-09-16 Janssen Pharmaceuticals, Inc. Substituted indazole and aza-indazole derivatives as gamma secretase modulators
US8946266B2 (en) 2009-07-15 2015-02-03 Janssen Pharmaceuticals, Inc. Substituted triazole and imidazole derivatives as gamma secretase modulators
US9145399B2 (en) 2010-01-15 2015-09-29 Janssen Pharmaceuticals, Inc. Substituted bicyclic triazole derivatives as gamma secretase modulators
US9079886B2 (en) 2010-01-15 2015-07-14 Janssen Pharmaceuticals, Inc. Substituted triazole derivatives as gamma secretase modulators
US10117858B2 (en) 2010-03-19 2018-11-06 Novartis Ag Pyridine and pyrazine derivative for the treatment of CF
US11911371B2 (en) 2010-03-19 2024-02-27 Novartis Ag Pyridine and pyrazine derivative for the treatment of chronic bronchitis
USRE46757E1 (en) 2010-03-19 2018-03-20 Novartis Ag Pyridine and pyrazine derivative for the treatment of CF
US9365552B2 (en) 2010-03-19 2016-06-14 Novartis Ag Pyridine and pyrazine derivative for the treatment of CF
US9550767B2 (en) 2010-05-17 2017-01-24 Forum Pharmaceuticals, Inc. Crystalline form of (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide hydrochloride monohydrate
US9108961B2 (en) 2010-05-17 2015-08-18 Forum Pharmaceuticals, Inc. Crystalline form of (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide hydrochloride
US9273044B2 (en) 2010-05-17 2016-03-01 Forum Pharmaceuticals, Inc. Crystalline form of (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide hydrochloride monohydrate
US9403815B2 (en) 2010-06-24 2016-08-02 The Regents Of The University Of California Compounds and uses thereof in modulating levels of various amyloid beta peptide alloforms
US8901309B2 (en) 2010-09-02 2014-12-02 Takeda Pharmaceutical Company Limited Fused triazoles for the treatment or prophylaxis of mild cognitive impairment
US8822699B2 (en) 2010-09-02 2014-09-02 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof
US8987276B2 (en) 2011-03-24 2015-03-24 Janssen Pharmaceuticals, Inc. Substituted triazolyl piperazine and triazolyl piperidine derivatives as gamma secretase modulators
US9067934B2 (en) 2011-03-31 2015-06-30 Pfizer Inc. Bicyclic pyridinones
US8697673B2 (en) 2011-03-31 2014-04-15 Pfizer Inc. Bicyclic pyridinones
US9115143B2 (en) 2011-07-15 2015-08-25 Janssen Pharmaceuticals, Inc. Substituted indole derivatives as gamma secretase modulators
US9585877B2 (en) 2012-05-08 2017-03-07 Forum Pharmaceuticals, Inc. Methods of maintaining, treating or improving cognitive function
US9181245B2 (en) 2012-05-16 2015-11-10 Janssen Pharmaceuticals, Inc. Substituted pyrido[1,2-a]pyrazines and substituted pyrido[1,2-a][1,4]diazepines for the treatment of (inter alia) Alzheimer's disease
US9751877B2 (en) 2012-09-21 2017-09-05 Pfizer Inc. Substituted pyrido[1,2-a]pyrazines for the treatment of neurodegenerative and neurological disorders
US8916564B2 (en) 2012-09-21 2014-12-23 Pfizer Inc. Substituted pyrido[1,2-a]pyrazines for the treatment of neurodegenerative and neurological disorders
US9193726B2 (en) 2012-09-21 2015-11-24 Pfizer Inc. Substituted pyrido[1,2-a]pyrazines for the treatment of neurodegenerative and neurological disorders
US10112943B2 (en) 2012-12-20 2018-10-30 Janssen Pharmaceutica Nv Substituted imidazoles as gamma secretase modulators
US10246454B2 (en) 2013-01-17 2019-04-02 Janssen Pharmaceutica Nv Substituted 3,4-dihydro-2H-pyrido[1,2-a]pyrazine-1,6-diones as gamma secretase modulators
US9938263B2 (en) 2013-03-12 2018-04-10 The General Hospital Corporation Gamma-secretase modulators
US11447478B2 (en) 2013-04-11 2022-09-20 Hoffmann-La Roche Inc. BACE1 inhibitors
US10472346B2 (en) 2014-10-31 2019-11-12 The General Hospital Corporation Potent gamma-secretase modulators
US11117884B2 (en) 2014-10-31 2021-09-14 The General Hospital Corporation Potent gamma-secretase modulators
US9765073B2 (en) 2015-02-03 2017-09-19 Pfizer Inc. Cyclopropabenzofuranyl pyridopyrazinediones
US10818850B2 (en) 2017-12-22 2020-10-27 Samsung Display Co., Ltd. Organic electroluminescence device and compound including nitrogen for organic electroluminescence device
US11905258B2 (en) 2018-02-21 2024-02-20 Southern Research Institute 2-aminoaryl-5-aryloxazole analogs for the treatment of neurodegenerative diseases
US11718593B2 (en) 2018-05-17 2023-08-08 Southern Research Institute 2,5-aryl-thiazole analogs for the treatment of neurodegenerative diseases

Also Published As

Publication number Publication date
JP2012051807A (ja) 2012-03-15
TW201035076A (en) 2010-10-01
AR075607A1 (es) 2011-04-20

Similar Documents

Publication Publication Date Title
WO2010098488A1 (fr) Composé arylimidazole et leur utilisation en tant qu'inhibiteurs de production de la protéine amyloïde bêta
WO2010098495A1 (fr) Dérivés d'imidazolylpyrazine
EP2559693B1 (fr) Composé polycyclique
EP2401276B1 (fr) Composés héterocycliques fusionnés contenant de l'azote et leur utilisation en tant qu'inhibiteurs de la production de beta amyloide
US7935815B2 (en) Imidazoyl pyridine compounds and salts thereof
EP1992618B1 (fr) Dérivé polycyclique de cinnamide
US7713993B2 (en) Multi-cycle cinnamide derivatives
EP2019094A1 (fr) Dérivé de cinnamide de type hétérocyclique

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10708825

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: JP

122 Ep: pct application non-entry in european phase

Ref document number: 10708825

Country of ref document: EP

Kind code of ref document: A1